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Abstract

Cytosine methylation (5mC) is essential for transcriptional control and genomic
stability and is often used as a prognostic marker in cancer. Although 5mC has long been
considered a relatively stable epigenetic mark, recent studies have demonstrated that it can
be

reversed

enzymatically

by

TET

proteins

which

oxidize

5mC

into

5-

hydroxymethylcytosine (5-hmC), and then to 5-formylcytosine (5-fC) and 5-carboxylcytosine
(5caC). This mechanism is known as active DNA demethylation and the base excision repair
enzyme Thymine DNA Glycosylase (TDG) plays an essential role in this process by removing
5-fC and 5-caC which are subsequently replaced by the unmethylated cytosine. Importantly,
homozygous loss of TDG in mice causes embryonic lethality and the observed defects are
consistent with a central role for TDG in active demethylation and protein scaffolding events.
I hypothesize that the dual catalytic and protein scaffolding activities of TDG are essential
for gene transcription and that TDG functions as a tumor suppressor in vivo by maintaining
epigenetic stability in cells.
In this study, I investigated the regulation of Hypermethylated in Cancer 1 (Hic1)
tumor suppressor to demonstrate that the dual catalytic and scaffolding activities of TDG
are essential for gene transcription of HIC1. In addition, I developed a conditional TDG
knockout mouse model to determine the role of TDG in development. Hic1 transcription
involves a transient accumulation of 5fC/5caC metabolites and the recruitment of an
RAR/RXR complex, both of which were found to be TDG dependent. Tdg deletion in vivo
causes Hic1 silencing via promoter DNA hypermethylation. In addition, a loss of TDG in
adult mice predisposes them to a high prevalence of hepatocellular carcinoma (HCC),
i

independent of cirrhosis or fibrosis. Surprisingly, HCC occurred predominantly in male
mice, which also showed increased obesity compared to age matched controls. RNAseq
analysis of livers from TDG deleted mice showed downregulation of several metabolism
relevant genes. These findings are consistent with an onset of HCC via the non-alcoholic fatty
liver pathway. Collectively, this study shows that the dual catalytic and scaffolding activities
of TDG are required in gene transcription events, and provides the first evidence of TDG as
a tumor suppressor of liver cancers.

Key Words: Hepatocellular carcinoma, non-cirrhotic/fibrotic pathway, NAFLD, active DNA
demethylation, TDG, TETs, HIC1, retinoic acid signaling
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Chapter 1: Introduction
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1.1 Epigenetic control of gene expression
The term “epigenetics” was first coined in 1942 to describe changes in an organisms
phenotype that occur independent of alterations in the DNA sequence (Waddington, 1942a,
1942b). The field of epigenetics gained prominence with the discovery of the histone code, which
along with DNA methylation, assists in gene expression by modulating the structure of chromatin
(Waddington, 1942a). Chromatin consists of condensed units of DNA, protein and RNA, and its
function is to package the genetic material into a more compact structure, prevent DNA damage
and control gene expression and replication (Barrero et al., 2010). Histones are the primary protein
components of chromatin, which facilitate DNA compaction through polar-polar interactions
between their positively charged tails and the negatively charged DNA backbone.

DNA

methylation is a chemical modification of the cytosine nucleotides, and its major function has been
classically to repress gene transcription. Numerous studies have now shown that epigenetic
mechanisms, in addition to the DNA sequence, work to modulate specific gene expression patterns
that dictate a multitude of cellular processes, such as signaling cascades in response to stimuli, and
cellular reprogramming (Barrero et al., 2010; Métivier et al., 2008). The technological advances
in

next

generation

sequencing

and

biochemical

techniques,

such

as

chromatin

immunoprecipitation and bisulfite sequencing, have enabled the analysis of the epigenome at or
near base-pair resolution and allowed epigenetic profiling in both normal and abnormal cells or
tissues. Most of these studies have demonstrated that epigenetic modifications of the chromatin
are dynamic and have defined critical DNA control elements, such as promoters and enhancers
(Chen et al., 2003b; Hassan et al., 2017; Iurlaro et al., 2016; Kolovos et al., 2012; Song et al.,
2013).
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The concept of nucleosome organization of chromatin was first proposed in 1974 as a
“chromatin subunit model” (Kornberg, 1974). In this model, it was proposed that chromatin is
composed of an array of nucleosome core particles. Each nucleosome consists of a stretch of DNA
(147 base pairs) wound around a histone octamer, which contains two copies of H2A, H2B, H3,
and H4. The individual nucleosome particles are separated by approximately 50 base pairs of linker
DNA and the linker histone H1. Furthermore, each histone possesses a positively charged Nterminal tail that protrudes outwards and can be covalently modified. The compaction of chromatin
into higher-order structures is mediated primarily by the N-terminal tails of histones H3 and H4,
which bind to the DNA and interact with acidic regions of histones within the neighboring
nucleosomes. Histone H1 binds the nucleosome at entry and exit sites of DNA, thus stabilizing the
formation of higher order chromatin structures. Posttranslational modifications (PTMs) of the
positively charged histone tails (e.g. acetylation, phosphorylation, and methylation) alters the
structure of chromatin and either provides access to gene material or facilitates further DNA
compaction. This remodeling of histone octamers, and thus the nucleosomes, leads to distinct
states of the chromatin generally characterized as heterochromatin and euchromatin, that reflect
different levels of gene activity (Allfrey et al., 1964; Allshire and Ekwall, 2015; Elgin and Reuter,
2013; Kayne et al., 1988; Megee et al., 1990; Pikaard et al., 2014; Verdin and Ott, 2014).
When stained with DAPI, heterochromatin appear as small, darkly staining, irregular
particles scattered throughout the nucleus that consist of tightly packed nucleosomes. The
heterochromatinization of DNA hinders gene transcription by masking binding sites for
transcription factors, RNA polymerases and other proteins essential for gene expression. These
heterochromatinized states are established by specific PTMs of the histone tails, such as
trimethylation of H3K27 or di- and tri-methylation of H3K9. These marks are deposited by a
3

multitude of coregulator proteins such as SUV39H1 (Melcher et al., 2000), which are often found
as part of larger protein complexes. For instance, the methylation of H3K9 (H3K9me3) by
SUV39H1 provides a docking site for chromodomain-containing heterchromatin protein 1 (HP1),
which then impairs nucleosome accessibility and induces gene repression (Bannister et al., 2001;
Melcher et al., 2000; Stewart et al., 2005).
In contrast, euchromatin consists of loosely packed chromatin and is enriched in genes
which are either poised or undergoing active transcription. Approximately 90% of the genome is
found in euchromatin. Many studies have now shown that acetylation of histone tails such as
H3K14 acetylation (H3K14ac) by nuclear histone-acetyltransferases, such as CBP and p55,
provide docking sites for bromodomain-containing proteins that further stimulate nucleosome
accessibility and transcriptional activity (Allfrey et al., 1964; Verdin and Ott, 2014). Furthermore,
covalent modifications affecting the histone tails can be reversed by histone deacetylases
(HDACs), which remove acetylCoA and re-establish the repressed chromatin state (Nagy et al.,
1997; Verdin and Ott, 2014). The balance between euchromatin and heterochromatin formation of
DNA, via the deposition and removal of specific histone marks, afford a powerful and highly
conserved route to gene expression. Evidence for this is provided by the HP1-SUV39H1-H3K9
histone methylation system for gene repression which is now known to be conserved across unicellular organisms, plants, invertebrates and complex multicellular organisms (Allshire and
Ekwall, 2015; Elgin and Reuter, 2013; Pikaard et al., 2014).

1.2 DNA methylation
In addition to the covalent modification of histones, the methylation of cytosine at the
5th carbon (5-mC) is the second major mechanism associated with epigenetic changes that has a
4

profound effect on gene expression. This modification occurs predominantly in the context of CpG
dinucleotides (Wu and Zhang, 2014), which are palindromic sequences of cytosine followed by a
guanine nucleotide. These dinucleotides are typically methylated in a symmetric fashion. Regions
with a high frequency of CpG sites (~ 60 % CpG composition) are referred to as CpG islands and
occur at or near the promoters of mammalian genes, where they act to repress gene transcription
when they are methylated. DNA methylation is also found within gene bodies of actively
transcribed genes, regulatory elements such as enhancers, and non-CpG promoters depending on
the cell type, although the role of CpG islands in these contexts remains unclear (Ito et al., 2011;
Shen et al., 2014; Wu et al., 2014). Roughly 60 – 80 % of CpG sites within the mammalian genome
are methylated (Smith and Meissner, 2013). Although the methylation of cytosine in non-CpG
context is prevalent in plants (Wu and Zhang, 2014), the 5mC mark in mammalian cells is most
commonly found in CpG sites.
The 5mC modification is important for a variety of biological processes including
transcriptional regulation, genomic imprinting, X-chromosome inactivation and the suppression
of mobile genetic elements (Wu and Zhang, 2014; Zhu, 2009). The deposition of the 5mC mark is
known to affect the transcription of genes in two ways. First, in the context of promoter CpG
islands, cytosine methylation contributes to transcriptional repression by affecting the affinity of
transcription factors for their binding sites. For example, methylation of the E-box DNA element
(CACGTG) prevents Myc from binding to the EGFR promoter in a cell-specific manner (Perini et
al., 2005). Secondly, the 5mC mark can also provide docking sites for proteins containing the
methyl binding domain (MBD). MBD proteins, such as MBD4 and MeCP2, are able to recruit
additional effector proteins such as histone deacetylases and methyltransferases which can modify
histones and increase chromatin compaction to further promote transcriptional repression (Fuks et
5

al., 2003). Another example of crosstalk between DNA methylation and histone modifications is
found in the repressive action of the G9A histone methyltransferase protein. G9A deposits
repressive methylation marks on histones and physically recruits the DNA methyltransferase
(DNMT) protein, which methylates DNA to suppress gene transcription (Estève et al., 2006).
DNA methylation in this example is not a cause, but a consequence of repression and serves to fix
the repressed state of chromatin. Evidence for the repressive role of 5mC is demonstrated by
studies using epigenetic drugs such as 5-azacytidine, a chemical analogue of the nucleoside
cytodine, that becomes incorporated into DNA and RNA and inhibits DNA methyltransferase
causing hypomethylation of the DNA. This results in transcriptional activation of genes silenced
by promoter DNA hypermethylation (Britschgi et al., 2008; Kafri et al., 1992).
While it is clear that cytosine methylation is a crucial gene regulatory mechanism, several
studies have challenged the notion that DNA methylation is always correlated with transcriptional
repression. For example, the transcription of some genes has been found to be independent of
methylation and in some cases, methylation is required for transcriptional activation and therefore,
is positively correlated with gene expression (Bird, 1984). Promoters with low CpG content are
usually methylated, yet they still may be transcriptionally active (Weber et al., 2007) Intergenic
and gene terminal CpG islands of some genes are frequently methylated, yet the genes they are
associated with are transcriptionally active (Medvedeva et al., 2010). The dynamic nature of DNA
methylation and proteins involved in this pathway will be the topic of discussion in the next
section.
1.3 DNA methylation is dynamic
The 5mC mark is faithfully reproduced over successive replication cycles by the
maintenance DNA methyltransferase 1 (DNMT1) protein, which catalyzes the transfer of a methyl
6

group from S-adenosylmethionine (SAM) to the C5 carbon of cytosine. In contrast, de novo
DNMTs (DNMT2, DNMT3a and DNMT3b) can deposit novel methylation marks on DNA in a
cell cycle independent manner. Despite cytosine methylation being primarily restricted to CpG
sites in somatic cells, which are symmetrically methylated, non-CpG methylation is relatively
abundant in oocytes, embryonic stem cells and mature neurons (Lister et al., 2009).
Although 5mC has long been considered a relatively stable epigenetic mark, recent studies
have demonstrated that DNA methylation, like histone modifications, is highly dynamic. There
are multiple pathways that have been proposed to demethylate 5mC: active modification of 5mC
followed by excision via TDG (active demethylation), passive dilution of 5mC and/or its oxidized
metabolites (passive demethylation) and direct removal of the 5mC mark.
The first evidence of active DNA demethylation was provided by studies showing that the
interleukin 2 promoter undergoes rapid DNA demethylation following T lymphocyte activation,
in a replication independent manner (Bruniquel and Schwartz, 2003). At that time, a unified
mechanism responsible for active demethylation was not definitively established. One mechanism
which has gained momentum involves base excision repair (BER) initiated by the DNA
glycosylase, thymine DNA glycosylase (TDG). It was subsequently demonstrated that the
promoters of several developmentally regulated genes underwent DNA hypermethylation upon
deletion of TDG in mice (Cortazar et al., 2011; Cortellino et al., 2011). Further studies
demonstrated that 5mC is not a direct substrate for TDG but is oxidized by Ten eleven translocase
(TET) family of proteins to 5-hydroxymethylcytosine (5-hmC), and then to 5-formylcytosine (5fC) and 5-carboxylcytosine (5caC) (Ito et al., 2011) (Figure 1.1B). 5fC and 5caC are recognized
and removed by TDG. This generates an abasic site which is then cleaved by AP endonuclease
and the unmethylated cytosine is then incorporated by DNA polymerase.
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The Ten eleven translocase (TET) proteins are iron (II)/ α-ketoglutarate (Fe(II)/α-KG)dependent dioxygenases that oxidize 5mC. TET proteins contain a core double-stranded β-helix
(DSBH) domain and a cysteine-rich (CXXC) domain. The DSBH domain of TETs brings the
Fe(II), α-KG and 5mC together in a catalytic pocket to facilitate 5mC oxidation, whereas, the
CXXC domain stabilizes the TET-DNA interaction. The full length TETs (TET1 and TET3)
contain both the DSBH and CXXC domains, whereas, the truncated TET2 lacks CXXC domain
(Wu and Zhang, 2017). Overall, these studies provide evidence of an active mechanism of DNA
demethylation, where oxidation of the methyl group produces metabolites that can be processed
by TDG and the BER pathway.
In passive DNA demethylation, the 5mC mark is diluted over successive replication cycles by
the deactivation or nuclear exclusion of maintenance DNMT1 or its associated co-factor, UHRF1
(Kohli and Zhang, 2013) (Figure 1.1A). Evidence for passive demethylation can be found in
studies on the role of demethylation metabolites in embryonic development. Immunostaining of
the early embryo has shown that loss of 5mC in the paternal genome is concomitant with
generation of 5hmC metabolites, which is dependent on the expression of TET3 protein—the only
highly expressed TET in the embryo (Gu et al., 2011; Guo et al., 2014; Tsukada et al., 2015).
Knockdown or the targeted germline deletion of TET3 abolished the oxidation of 5mC in the
paternal genome and led to reduced fertility and developmental failure in the offspring (Gu et al.,
2011; Guo et al., 2014). Despite finding that only the paternal DNA undergoes 5mC oxidation,
both the maternal and paternal genomes are demethylated via passive dilution (Wu and Zhang,
2014). The reason for selective oxidation of the paternal genome is currently unclear. On another
note, although the passive demethylation pathway proceeds via dilution of the methylated DNA
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strand to regenerate cytosine, the initial oxidation of 5mC is an active process. Hence, it is useful
to consider this process as partially active rather than entirely passive.
In addition to passive dilution, the simplest route to regenerate unmethylated cytosine is a
direct removal of the 5mC mark. This process poses a very large energy barrier due to the high
stability of the covalent bond (carbon to carbon) linking the methyl group to C5 of cytosine.
However, despite this energy barrier, plants utilize DEMETER/ROS1 class of proteins which
directly remove 5mC without any oxidative modification of 5mC (Mok et al., 2010; Morales-Ruiz
et al., 2006). In mammals, however, orthologues for DEMETER/ROS1 have not been identified
so the most widely accepted mechanisms for restoring unmethylated cytosine involves two
pathways: passive dilution and active DNA demethylation. Active demethylation involves
oxidation of 5mC followed by replacement of oxidized substrates by TDG and members of the
BER pathway.

1.4 Role of TDG in active DNA demethylation
Prior to the discovery of 5mC oxidation, initial studies on active demethylation supported a
mechanism involving the deamination pathway (Nabel et al., 2012; Piccolo and Fisher, 2014;
Thillainadesan et al., 2012; Zhu, 2009). It is well established that 5mC can be deaminated to
thymine by the AID/APOBEC family of enzymes. This would generate a G-T mispair which is
then excised by TDG. In addition, it was proposed that AID/APOBEC could deaminate 5hmC to
5-hydroxymethyluracil (5hmU) which is then excised by TDG. However, a study by Nabel et al.
(2012) refuted this model since AID/APOBEC proteins were found to have little to no deamination
activity on either 5mC or 5hmC in vitro (Nabel et al., 2012). In contrast, AID/APOBEC displayed
the highest preference towards the less bulky unmethylated cytosine nucleotide due to reduced
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steric hindrance. These findings were further supported by the observation that there are no
significant developmental defects associated with AID/APOBEC deficiency. Overall, these results
suggest that deamination-coupled demethylation is unlikely to be involved in active
demethylation, and that this process likely proceeds via a TET and TDG-dependant pathway.
Unlike other proteins in its class, TDG is the only glycosylase essential for embryonic
development (Cortázar et al., 2011; Cortellino et al., 2011). Homozygous loss of Tdg in the embryo
correlated with decreased expression of developmental transcription factors with a marked
increase in methylation at many regulatory sites. This led both studies to conclude that TDG is
required to maintain epigenetic stability in cells. Surprisingly it was demonstrated that 5mC or
5hmC are not direct substrates for TDG. As stated above, 5mC and 5hmC could be metabolized
further by TET proteins to 5fC and 5caC (Ito et al, 2011). Importantly, biochemical studies
demonstrated that TDG possesses robust activity against 5fC and 5caC when paired with G in vitro
and in vivo (Shen et al., 2013; Maiti et al., 2011; He et al., 2010). TDG was found to have a very
high affinity for these metabolites and studies using mouse embryonic stem cells demonstrated
that 5fC/5caC intermediates can be found at low levels throughout the genome and accumulate
upon TDG deletion (Hu et al., 2014; Shen et al., 2013, 2014; Spruijt et al., 2013; Wu et al., 2014).
These findings demonstrate that TDG acts directly on TET oxidation products.
In the TET/TDG model of active DNA demethylation, TDG catalyzes the excision of 5-fC and
5-caC metabolites. This forms an apurinic (AP) site and the combined actions of APE1, DNA pol
β and XRCC1- DNA ligase IIIα complex subsequently replace the AP site with an unmethylated
cytosine (Figure 1.1B). In this model, TDG functions as the focal point between TET mediated
5mC oxidation and BER, which underscores its importance in maintenance of epigenetic stability
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Figure 1. 1 The 5mC mark can be removed by both passive and active processes

(A) Passive DNA demethylation is initiated by the silencing or nuclear exclusion of DNMT or its
associated cofactor UHRF1. This pathway leads to loss of the maintenance methylation machinery
and the methylated DNA strand is diluted over successive replication cycles. The methylated DNA
strand is colored in blue.
(B) TET- and TDG-mediated active DNA demethylation. DNMT’s deposit the methylation mark
on cytosine (C) at the 5th carbon. Then, TET proteins successively oxidize the 5-methylcytosine
(5mC) to 5-hydroxymethylcytosine (5hmC), 5-formylcytosine (5fC) and 5-carboxycytosine
(5caC). The 5fC and 5caC intermediates are excised by TDG leading to an apurinic (AP) site that
is repaired by proteins from the base excision repair (BER) pathway: APE1, DNA pol β, and
XRCC1-DNA ligase IIIα complex and unmethylated cytosine is restored.

The “R” group

represents the deoxyribose sugar component of the nucleotide.
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in cells. The mechanism of recognition and subsequent excision of 5fC/5caC by TDG is the topic
of discussion in the next section.

1.5 Structure of the TDG protein
Thymine DNA glycosylase is a BER protein that belongs to the uracil DNA glycosylase
(UDG) superfamily of enzymes that share a common α/β fold (Aravind and Koonin, 2000; Aravind
et al., 2000; Cortázar et al., 2007; Mol et al., 1995; Neddermann and Jiricny, 1993; Pearl, 2000;
Wiebauer and Jiricny, 1989). It was first purified from HeLa cell extracts and its initial biochemical
properties were consistent with a central role in removing mutagenic 5-methylcytosine
deamination products from DNA (Neddermann and Jiricny, 1993). TDG is capable of recognizing
G:T and G:U mismatches in the DNA and restore the correct G:C base pairs through BER
(Cortazar et al., 2007).
The human TDG (410 amino acids) consists of a highly conserved catalytic core (121 – 300
amino acids) that is flanked by variable amino and carboxyl terminal domains (Cortázar et al.,
2007) (Figure 2). The amino and carboxy termini of TDG contain sites for SUMO conjugation
(K330 and E310), whereas, the carboxyl terminal domain enhances its affinity for DNA and
contains the catalytic activity (Cortázar et al., 2007; McLaughlin et al., 2016). The terminal
domains have also been shown to mediate diverse physical interactions with various nuclear
receptors and other transcription factors and could potentially dictate targeting of TDG to specific
DNA loci via accommodating specific interactions with its partners. TDG has also been shown to
interact with numerous chromatin remodeling enzymes and DNMTs (Cortázar et al., 2007, 2011;
Li et al., 2007), raising the possibility of a functional role of TDG in modulating gene transcription,
either through its glycosylase activity or as a scaffold protein and/or transcriptional coactivator.
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1.6 Mechanism of action of TDG
TDG has been the subject of compelling structural studies since the discovery of its unique
role in recognition and excision of 5fC/5caC metabolites, as well as, T:G mispairs from DNA. The
crystal structure of TDG catalytic domain bound to DNA revealed a 2:1 dimeric complex with the
DNA, with one subunit being positioned at the abasic site forming the product complex, and the
other at a non-specific site roughly 10 base pairs away (Maiti et al., 2008). The dimer was found
to exist exclusively in the presence of DNA. Although the biological roles of dimer formation
remain unclear, it could play an important role in transcriptional regulation through potential
interactions with DNMT’s, chromatin remodeling proteins or co-activators such as CBP/ p300.
Upon binding to DNA, TDG causes the nucleotide to flip out of the double-helix and into the
active site. The catalytic site of TDG forms various contacts with the abasic strand, involving
phosphodiester groups flanking the abasic nucleotide, sugar and both guanines of the CpG site.
The interactions with phosphates in the complementary strand is made by using side chains of
K246 and K248, both of which are highly conserved in vertebrates. The phosphates belonging to
the abasic nucleotide is displaced from the double helix and resides in the active-site pocket in a
phenomenon called a “phosphate pinch” which facilitates nucleotide flipping. In the active site of
TDG, residues 198- 200 cover the face of the flipped nucleotide, thereby preventing its re-insertion
back into the double helix. Overall, the extensive interactions of TDG with the flipped nucleotide
and backbone sugars of both DNA strands provides an explanation for the slow turnover of TDG
bound DNA and its high affinity for the AP site (Baba et al., 2005; Cortázar et al., 2007; Maiti et
al., 2008).
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Figure 1. 2 Schematic representation of the TDG protein

Schematic representation of wild type TDG and positions of the relevant amino acids and posttranslational modifications--Ac: acetylation site, DBD: DNA binding domain, NRs: nuclear
receptors, SBD: SUMO binding domain, S: SUMOylation site
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The crystal structure of TDG bound to 5caC-containing DNA confirmed a 2:1 binding, with
the 5caC base being recognized by only one of the TDG molecules (Hashimoto et al., 2013; Zhang
et al., 2012). TDG was found to bend the DNA backbone and flip 5caC out of the double helix,
while R275 facilitates this process by wedging through the dsDNA minor groove and pushing
5caC into the active site of TDG. The R275 amino acid enhances the nucleotide flipping
mechanism, while simultaneously increasing DNA binding affinity of TDG. Overall, this
remarkable “base-flipping” process involves rotation of the 5caC pyrimidine along the glycosylic
bond, which causes the whole base to penetrate the active site pocket of TDG.
Once inside the active site pocket of TDG, the 5caC base is locked via polar interactions from
the surrounding amino acids: lle139, Ala140 and Asn191. In addition to these interactions, the
carboxyl moiety of 5caC is specifically recognized in a small pocket formed via the side chains of
several amino acids in the catalytic site. Particularly, the carboxyl group forms specific hydrogen
bonding interactions with the backbone amide of Tyr152 and the side chain of Asn157, as well as,
van der Waals contact with the side chain of Ala145. It is predicted that these polar interactions
enhance the binding affinity of TDG for 5caC and 5fC metabolites over U and T.
Kinetic studies on TDG demonstrate that it possesses little to no activity against 5mC, 5hmC
or C paired with G in vitro (Waters and Swann, 1998). In contrast, TDG was shown to rapidly
excise 5fC and 5caC from dsDNA with a Kmax of 2.64/min and 0.47/min, respectively (Waters and
Swann, 1998). The preference for T:G mispairs fell between that of 5fC and 5caC, with a Kmax of
1.83/min. These studies demonstrate that TDG can recognize 5fC and 5caC with high specificity,
and through the base-flipping mechanism, facilitate the rapid excision of these metabolites from
dsDNA. These unique characteristics position TDG as the only glycosylase capable of recognizing
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and excising TET oxidation products from dsDNA and establishes its essential role in active DNA
demethylation.
As discussed above, TDG has a very high affinity for the AP site, which makes the physical
removal of TDG from DNA a rate limiting step in BER. Despite this potential roadblock for the
repair pathway, the slow turnover of TDG is important since a naked AP site would predispose the
DNA to single and double strand breaks. This could drastically increase the mutability and
integrity of DNA over time.
Many studies support the role of SUMOylation in facilitating TDG turnover from the AP site.
Small Ubiquitin like Modifiers (SUMOs) are small peptides that interact with or are attached to
other proteins (Jürgen Dohmen, 2004). Many of the SUMO target proteins participate in DNA
replication or repair, which highlights its potential role in maintaining genome integrity and
stability. SUMOylation induces a conformational change in the target proteins in a way that alters
their protein:protein and/or protein: DNA interaction properties. In the case of TDG, SUMOylation
at K330 causes protrusion of the C-terminal α helix and induces severe steric clash with the sugarphosphate backbone of the unpaired G (Baba et al., 2005). This in turn causes dissociation of
SUMO-1-TDG from AP site. Interestingly, the SUMOylation event doesn’t change the structure
of SUMO-1, nor does it encounter steric interference from the DNA.
Besides SUMOYlation of TDG, there are other proteins that affect its activity. Two of the most
interesting proteins are GADD45 (growth arrest and DNA-damage-inducible protein 45) and NEIL
(Nei endonuclease VIII-like family of DNA glycosylases). GADD45 is a multi-faceted nuclear
protein which has been implicated in DNA demethylation, DNA repair and genomic stability.
Overexpression of GADD45 leads to global DNA demethylation in the presence of TDG and TET
proteins (Li et al., 2015). These studies propose that GADD45 enhances DNA demethylation by
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TDG, although the mechanism remains unknown. NEILs, on the other hand, provide an alternative
to SUMOYlation for facilitating TDG turnover by displacing TDG from the AP site and removing
the baseless sugar. Interestingly, NEIL1 and 2 were also identified as 5fC binders and are
implicated in excising these oxidized metabolites from genomic DNA, albeit at a much lower
efficiency compared to TDG (Schomacher et al., 2016; Slyvka et al., 2017). Although the
mechanism behind GADD45 and NEILs actions is unclear, the involvement of a wide multitude
of proteins in TDG mediated active DNA demethylation highlights the complex nature of this
process.

1.7 Role of TDG in transcription regulation
TDG is the only glycosylase in mammals that is essential for embryonic development
(Cortázar et al., 2011; Cortellino et al., 2011). Tdg null embryos display a complex phenotype of
liver and pericardial hemorrhages, hypoplastic branchial arteries, as well as delayed limb
development. There were pronounced defects in the heart tissue, with prominent abnormalities in
the outflow tract, vasculogenesis and angiogenesis. The consistency and sudden onset of lethality
in Tdg null embryos was a very surprising observation, since a prominent role of TDG in base
repair should have led to a more variable phenotype resulting from a wide spectrum of genetic
mutations. However, mutations in the TDG KO mice were not identified and it became apparent
from these studies that TDG plays a predominant role in transcriptional regulation in addition to
BER.
Tdg null embryos displayed 33% viability at E11.5 with complete reabsorption at E12.5, a
time interval when the mouse genome undergoes epigenetic reprogramming and imprint erasure
(Hackett et al., 2013). Loss of TDG at E11.5 caused gene expression defects of numerous
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developmentally regulated genes most likely resulting from loss of recruitment of additional
coregulators such as CBP/p300, as well DNA hypermethylation, the loss of active chromatin marks
and the accumulation of repressive marks (Cortázar et al., 2011; Cortellino et al., 2011; Hajkova
et al., 2010). These findings were consistent with a central role of TDG in transcription via genespecific DNA demethylation and establishment of histone marks during development.
Interestingly, both knockout studies demonstrated that deletion of TDG in embryos severely
impairs retinoid signaling pathways (Cortellino et al., 2011; Um et al., 1998). Furthermore, many
of the phenotypical features observed in TDG null embryos were found to be common among
RXR and RAR null embryos (Cortellino et al., 2011). TDG has also been shown to interact with
RARα, RXRα and other nuclear receptors such as PPARα, ERα, TTF1, AR, TR, and GR (Chen
et al., 2003a)
In addition to interactions with nuclear receptors, TDG was found to associate with other
transcription factors and coregulators such as TCF4, SRC1, SMADs, p/CIP, p53 and CBP/p300
(Cortázar et al., 2007; Léger et al., 2014; Métivier et al., 2008; Thillainadesan et al., 2012; Tini et
al., 2002). This comprehensive interaction network depicts TDG as a potential hub protein and an
important player in protein complex stability at target genes. Evidence for this was provided using
chromatin immunoprecipitation studies showing that the recruitment of CBP, MLL1 and other
proteins at target genes are lost upon TDG deletion (Cortellino et al., 2011). This in turn affects
gene expression due to the attenuated deposition of active histone marks, such as H3K4 trimethylation and H3K4 acetylation, which are more permissive for gene transcription.
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1.8 Summary of objectives
In lieu of the myriad of interactions of TDG with transcription factors, it became important
to reconcile its glycosylase activity in gene transcription. The initial knockout papers demonstrated
that a loss of TDG leads to gene specific hypermethylation, whereas, studies on mESC
demonstrated a global accumulation of 5fC/5caC metabolites (Shen et al., 2013; Wu et al., 2014).
Although these studies shed light on the relevance of TDG in active DNA demethylation, they
show conflicting evidence and failed to provide a mechanism by which these metabolites are
generated and excised by TDG. Furthermore, there is no study that reconciles the role of TDG
dependent active DNA demethylation, involving the generation and excision of 5fC/5caC
metabolites, and its scaffolding properties in gene regulation. First, to determine if the scaffolding
and catalytic activities of TDG are important in gene regulation, I have examined its role in retinoid
signaling events which was previously shown to be disrupted upon TDG deletion in embryos (Aim
1). Second, despite several studies implicating the importance of active DNA demethylation in
embryonic development, little is known regarding the requirement for TDG in adult physiology.
Hence, the second objective of my studies is to characterize the conditional deletion of TDG in
adult mice and elucidate its role in post embryonic development (Aim 2). I hypothesize that active
demethylation and the protein scaffolding activities of TDG are required for gene transcription and
that TDG functions as a tumor suppressor in vivo that regulates gene expression by maintaining
epigenetic stability in cells.

Aim 1: Examine the role of TDG in retinoid signaling events (Chapter 2)
In Chapter 2, I attempt to consolidate the dual catalytic and scaffolding activities of TDG
in a single mechanistic model by focusing on its importance in retinoid signaling events. Retinoic
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acid (RA), the bioactive metabolite of vitamin A, plays a critical regulatory role during embryonic
development, cellular homeostasis and differentiation of adult tissues by binding to heterodimers
of retinoic acid receptor α (RARα) and retinoid X receptor α (RXRα) proteins (Tang and Gudas,
2011). RA has also been characterized as a cell-cycle inhibitor by modulating the levels of p21CIP1
and p27 KIP1 kinase inhibitors which arrest the cells in G0/G1 phase of mitosis (Li et al., 2004; Suzui
et al., 2004). The binding of RA to RARα induces a conformational change in the receptor that
regulates the transcription of its target genes by recruiting coregulatory proteins (i.e. CBP/p300,
SRC, TDG, p/CIP). Interestingly, although RARs are rarely mutated in cancer, it has been reported
that tumours lose sensitivity to RA often due to DNA hypermethylation of retinoid regulated genes
(Tang and Gudas, 2011).
To examine the dual catalytic and scaffolding activities of TDG in RA signaling, we
identified Hypermethylated in Cancer 1 gene (Hic1) as a novel RA inducible target and examined
the mechanism of its regulation in mouse embryonic fibroblasts (MEFs). The Hic1 gene, located
at genomic location 11p13.3, encodes a zinc-finger transcriptional repressor that belongs to the
POZ family of proteins (Britschgi et al., 2008). HIC1 expression is often lost in solid human
cancers and leukemia as a result of DNA hypermethylation of its promoter, which results in
increased tumor cell proliferation, angiogenesis and metastasis (Aggerholm et al., 2006; Chen et
al., 2003b; Cheng et al., 2014; Jenal et al., 2010). Furthermore, studies have shown that HIC1
expression in cancer can be restored via UV irradiation and 5-azacytidine (Britschgi et al., 2006),
suggesting that mechanisms are in place for removing methylation. I show that treatment of MEFs
with RA leads to a rapid recruitment of an RAR complex consisting of TDG, the lysine
acetyltransferase CBP and TET1/2 to the Hic1 locus. The binding of this complex preceded loss
of the 5mC mark, and the simultaneous accumulation of 5fC/5caC at the Hic1 promoter. Through
22

time-course methylase assisted bisulfite sequencing (MAB-seq), which allows the base resolution
mapping of 5fC/5caC, I demonstrate that the subsequent excision of these metabolites occurs in a
TDG dependent manner. In addition, I found that the recruitment of CBP and TET2 at Hic1 was
TDG dependent, which is supported by a recent finding that TDG interacts with all three TET
isoforms (Udo et al., 2014). These findings provide evidence of TDG as a transcriptional regulator
of Hic1 by dual functionality: as a scaffold protein by facilitating the recruitment of TET2 and
CBP, and a glycosylase by removing 5fC/5caC metabolites generated during HIC1 transcription.

Aim 2: Characterize the role of TDG in vivo (Chapter 3)
TDG was originally defined as a G:T or G:U mismatch repair protein. Upon discovery of
TET mediated 5mC oxidation and the subsequent excision of 5fC/5caC by TDG, its role in active
DNA demethylation was confirmed. It has been established that TDG is a critical component of
the active DNA demethylation mechanism that functions directly downstream of TETs, and TDG
is the only known protein in mammalian systems capable of excising 5fC/5caC metabolites.
However, despite the discovery of the role of TDG in active DNA demethylation, its function in
post-embryonic development and physiology is unknown. In addition to the constitutive knockout
of TDG, evidence for the physiological relevance of TDG mediated active DNA demethylation
was provided by a study on somatic cell reprogramming. Hu et al. (2014) show that TDG, along
with all TET proteins, is essential for mesenchymal to epithelial transition (MET) during the
reprogramming of MEFs to induced pluripotent stem cells (Hu et al., 2014). This study showed
that 5mC, which is present at regulatory regions, undergoes TET mediated oxidation to 5fC/5caC
during the reprogramming process which are then excised by TDG. Remarkably, the
reprogramming of MEFs deficient in TDG was completely impaired. This study was important,
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since it correlated the generation and excision of 5fC/5caC to transcription and dedifferentiation,
and provided evidence for TDG dependent active DNA demethylation in a biologically relevant
process. However, despite these findings, there is no published study that directly addresses the
role of TDG in post embryonic development in vivo.
To determine the role of TDG in adult physiology in vivo, we generated Tdgfl/- UBCCre/ERT2+ mice. In this line, CreERT2 is expressed widely under the control of the ubiquitin C
(UBC) promoter and is inducible by tamoxifen (TAM) (Chapter 3). I demonstrate that the
conditional deletion of Tdg predisposes mice to hepatocellular carcinoma (HCC) through the noncirrhotic/non-fibrotic pathway (NCF pathway). Interestingly, a few mice developed
hepatoblastoma (HB) in addition to HCC. RNAseq of solid tumors and livers from male mice
deficient in TDG, depicted a downregulation in metabolism and p75NTR signaling, and
upregulation of the MAPK and HIPPO signaling pathways. In our mouse model, the onset of HCC
occurred predominantly in male mice, which display increased obesity and a dysregulation in
metabolism relevant genes. These findings suggest that TDG potentially regulates the nonalcoholic fatty liver (NAFLD) pathway of liver cancer. NAFLD is a disease that involves fat
deposition on the liver due to increased obesity, which is directly related to insulin resistance and
metabolic syndrome in humans and mice (Kettner et al., 2016; Phillips et al., 2006). Although, a
direct connection to NAFLD remains to be resolved, my study suggests that a loss of TDG in adult
mice leads to HCC formation through the NCF-NAFLD pathway.
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Chapter 2: Regulation of active demethylation through RAR-mediated recruitment of a
TET/TDG complex.
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2.1 Introduction
Derivatives of vitamin A, such as all-trans retinoic acid (ATRA), regulate a complex
network of genes involved in cell proliferation, differentiation and apoptosis; while, aberrant RA
signaling has been found in many cancers (Tang & Gudas, 2011). RA mediates its biological
effects by binding to and activating the retinoic acid receptors (RARα, β) that function primarily
by forming heterodimers with the Retinoid X receptors (RXRs) (Tang & Gudas, 2011).
RAR/RXRs belong to the superfamily of nuclear hormone receptors (NRs) that function as ligandactivated transcription factors to regulate the expression of target genes (Tang & Gudas, 2011). In
the absence of ligand, or in the presence of specific antagonists, RARs/RXRs actively repress
transcription by interacting with specific corepressor proteins such as the Nuclear Receptor
Corepressor (N-CoR) or Silencing Mediator of Retinoic Acid and Thyroid hormone receptor
(SMRT) (Nagy et al., 1997; Zamir et al., 1996). Agonist binding triggers a specific conformational
change in the receptor that facilitates the release of corepressor proteins and recruitment of
coactivator proteins. Many coactivators have been identified for the ligand-bound RAR/RXR
which provides a highly complex framework for coordinating transcription of target genes.
Thymine DNA Glycosylase (TDG) catalyzes the first step in a base excision repair pathway
that removes thymine or uracil from G:T or G:U mismatches. TDG also functions as a coactivator
and has been implicated in transcriptional control and gene expression by interacting directly with
various transcription factors such as the RAR, RXR, ER and TCF4 (Léger et al., 2014; Um et al.,
1998; Tini et al., 2002; Chen et al., 2003b; Jia et al., 2014). Furthermore, TDG interacts with the
lysine acetyltransferases CBP, and its paralog p300, and in vitro studies have revealed that the
CBP/TDG containing complexes can remove G:T/U mispairs as well as mediate histone
acetylation (Tini et al., 2002; Léger et al., 2014).
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More recent studies have established a central role for TDG in epigenetic regulation
involving DNA demethylation (Cortázar et al., 2011; Cortellino et al., 2011). DNA methylation
occurs primarily at cytosine:guanine dinucleotides (CpGs) and is catalyzed by DNA
methyltransferases (DNMT1, 3a and 3b), which transfer a methyl group from Sadenosylmethionine (SAM) to the C5 carbon of cytosine (5mC) (Cheng & Blumenthal, 2008).
Cytosine methylation in this context silences gene expression and is essential for differentiation
and development (Kafri et al., 1992). DNA methylation is generally regarded as a stable
modification, but at many regulatory sites DNA methylation is dynamic and is determined by a
balance between DNA methylation and demethylation events. Two general mechanisms have been
identified for DNA demethylation. Passive demethylation occurs when newly synthesized DNA
strands remain unmethylated during successive rounds of DNA replication as a result of reduced
DNMT activity (Oswald et al., 2000; Kafri et al., 1992; Wu & Zhang, 2010). In contrast, active
demethylation is a replication independent process that involves the Ten Eleven Translocation
(TET 1-3) enzymes which oxidize 5mC to 5-hydroxymethylcytosine (5hmC) in a 2-oxoglutarate
and Fe (II) dependent reaction. Subsequently, 5hmC is then metabolized by TETs into 5formylcytosine (5fC) and 5-carboxylcytosine (5caC) (Ito et al., 2011). These oxidized 5mC
metabolites, 5fC and 5caC, are recognized and removed by TDG. This generates an abasic site
which is cleaved by AP endonuclease and unmethylated cytosine is then incorporated by DNA
polymerase (He et al., 2010; Weber et al., 2016).
TDG is the only known enzyme that can excise 5fC and 5caC from dsDNA (Globisch et
al., 2010; He et al., 2010; Ito et al., 2011; Maiti & Drohat, 2011). Furthermore, 5fC/5caC, as well
as 5hmC, accumulate at many regulatory sites. This suggests that they may function as stable
modifications to modulate biological activity in addition to their role as demethylation
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intermediates. In further support of this function, recent in vitro studies have identified distinct
proteins that are recruited by 5hmC/5fC/5caC (Spruijt et al., 2013). Deletion of Tdg in the
germline is embryonic lethal and leads to DNA hypermethylation with associated defects in the
expression of various developmentally regulated genes (Cortázar et al., 2011; Cortellino et al.,
2011). Furthermore, it was found that TDG is essential for recruiting the acetyltransferases CBP
and p300, as well as other histone modifying enzymes, to a subset of target genes and Tdg null ES
cells fail to differentiate in response to RA (Cortázar et al., 2011). Importantly, 5fC and 5caC
levels increase five to ten fold genome wide in Tdg null ES cells (Shen et al., 2014). These findings
are consistent with the notion that TDG plays a central role in epigenetic stability and methylation
control and is essential for normal cellular homeostasis.
In the present study, we have identified the gene Hypermethylated in cancer 1 (Hic1) as
a novel RAR direct target gene and examined the mechanism of its regulation in MEFs. HIC1
expression is often lost in solid cancers and leukemia as a result of DNA hypermethylation of its
promoter and Hic1 heterologous mice exhibit an increased tumor burden (Mohammad et al., 2011;
Aggerholm et al., 2006; Chen et al., 2003a; Cheng et al., 2014; Jenal et al., 2010). We show that
treatment of MEFs with an RA agonist leads to a rapid recruitment of a multi-protein complex
consisting of RAR/RXR, CBP, TDG, TET1 and TET2 at proximal and distal regions of the Hic1
gene that encompass novel RA response elements (RARE). RA treatment also triggers a 3dimensional reorganization of chromatin, connecting a proximal 5’ RARE with a distal 3’ RARE.
Importantly, we show for the first time that the formation of this complex, in response to RA
correlates with a transient accumulation of 5fC/5caC at the Hic1 promoter that is TDG-dependent.
This mechanism of action is not restricted to Hic1, as another RAR target gene, Rarβ, is regulated
in a similar fashion. TDG deletion in adult mice causes hypermethylation of the Hic1 locus with a
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concomitant loss of HIC1 expression. Collectively, the present study suggests that active DNA
demethylation involving TDG is an essential step in Hic1 and Rarβ induction and that deregulation
of this mechanism may contribute to aberrant epigenetic silencing of these genes in cancer.
2.2 Results
2.2.1 Hic1 is an RAR target gene
Retinoids regulate mesenchymal progenitor (MP) behavior and differentiation (Cash et al.,
1997; Weston et al., 2000; Weston et al., 2002; Hoffman et al., 2006; Dranse et al., 2011). To
better understand the molecular basis of RA action in MP cells, we sought to identify relevant
RAR target genes. In previous studies, using primary limb mesenchyme (PLM) cultures, treatment
with bone morphogenetic protein-4 (BMP4) or other BMPs reduced expression of the RA
synthesis enzyme, Aldh1a2, and this was associated with decreased RA signaling (Hoffman et al.,
2006). Hierarchical clustering was performed on these datasets (Hoffman et al., 2006) to identify
genes that co-clustered with known RAR target genes, Rarβ and Cyp26a1 (Figure 2.1 A). Hic1
was identified as a gene that most tightly co-clustered with Cyp26a1. Consistent with Hic1 being
an RA-regulated gene, manipulation of RA signaling in PLM cultures using various
pharmacological agents, led to changes in expression of Hic1 (Figure 2.1 B). Treatment with alltrans retinoic acid (ATRA) or ketoconazole (a broad cytochrome P450 inhibitor that prevents RA
degradation) increased Hic1 expression. In contrast, treatment with either BMP4 or a pan-RAR
antagonist (4310) decreased Hic1 expression. Congruent with these observations, manipulation
of RA signaling in embryos with ATRA or 4310, increased and decreased Hic1 expression,
respectively (Figure 2.1 C). Deletion of the gene encoding the RA degradative enzyme Cyp26b1
leads to significant skeletal malformations and increased RA signaling (Dranse et al., 2011;
Pennimpede
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Figure 2. 1 Transcriptional activation of the Hic1 gene
(A) Transcriptional profiling of PLM cultures following treatment with BMP4 (20 ng/ml; 24B and
72B). Hierarchical clustering was used to identify genes that co-cluster with known RAR target
genes, Cyp26a1 and Rarβ.
(B) Analysis of Hic1 expression in PLM cultures following manipulation of RA signaling with
ketoconazole (keto), ATRA (100 nM), BMP4 (20 ng/ml) and AGN194310 (100 nM).
(C) Assessment of Hic1 expression in limb buds following administration of either ATRA (100
mg/kg) or AGN194310 (4310, 100 mg/kg) for 8h to pregnant dams at embryonic day E12.5.
(D) RNA analysis of Hic1 in MEFs treated with EC23 for various time periods. MEFs were grown
to confluency and then treated with EC23 as indicated. RNA was extracted and analyzed by qPCR.
Significance indicated as *, p < 0.05.
(E) Western Blot analysis of HIC1 and RARα in MEFs treated with EC23. MEFS were isolated
and treated with EC23 for various time periods. Proteins were isolated and analyzed by SDSPAGE and immunoblotting (IB) was performed using the indicated antibodies.
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et al., 2010). Analysis of Hic1 and for comparison Rarβ expression, revealed that both genes were
significantly upregulated in the Cyp26b1 null background (Figure 2.2 A). Analysis of RA
signaling activity in the limbs from transgenic mice containing an RARE-LacZ reporter showed
that the staining pattern of endogenous Hic1 expression is similar to the staining pattern for LacZ
activity, especially in those regions flanking the developing digits (Figure 2.2 B). RA-dependent
induction of the Hic1 transcript was also observed in embryonic day 14 MEFs treated with the
photo-stable RAR agonist EC23 (Figure 2.1 E). MEFs contain a mixture of mesenchymal cell
types and are comparable to the aforementioned utilized PLMs. Under similar conditions, HIC1
protein expression paralleled that observed for Hic1 mRNA (Figure 2.1 D). Interestingly, the
increase in Hic1 expression observed in MEFs was not evident in cancer cell lines. In most tumours
or cancer cell lines, Hic1 is either silenced or expressed at very low levels, often because of
hypermethylation of the Hic1 promoter (Jenal et al., 2010, Chen et al., 2003a). For example, in
MCF7 cells, HIC1 was detected at very low levels but was not upregulated in response to RA
(Figure 2.3 A). Nevertheless, loss of Hic1 expression was observed when TDG was downregulated
with siRNA. Together, these observations demonstrate that Hic1 expression is regulated by RA.
Previous studies have shown that RAR/RXR proteins form a ternary complex with TDG
and CBP, or its paralog p300 (Tini et al., 2002). To confirm RAR and CBP as TDG interacting
partners, we generated a stable HT1080 cell line containing a single copy insertion of FLAG-TDG
cDNA and utilized a reversible crosslink immunoprecipitation (ReCLIP) technique (Figure 2.3 B).
Western blotting indicated an upward shift in the TDG band upon RA treatment and crosslinking,
indicating formation of a TDG complex (Figure 2.3 C). Using this approach, we were able to
immunoprecipitate both RAR and CBP with FLAG-TDG upon RA treatment (Figure 2.3 D).
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The Hic1 locus contains three separate promoters P0, P1 and P2 that give rise to alternative
exons (1a, 1b and 1c) and a common exon 2 (Figure 2.4 A) (Gue et al., 2004; Guerardel et al.,
2001). The P0 promoter is associated with exon 1b and based on our analysis and others, only
exon 1b and 2 are potentially coding (Britschgi et al., 2006). Inspection of the Hic1 promoter
region revealed a phylogenetically conserved direct repeat 5 (DR5) canonical RARE (proximal
RARE) approximately 650 bp upstream of the TATA box containing P0 promoter. A second DR5
(distal RARE) was identified approximately 25 kb downstream of exon 2 (Figure 2.5 A). To assess
occupancy in response to RA, quantitative ChIP assays were performed using primer sets
encompassing specific regions of the Hic1 locus. Treatment of MEFs with RA for 90 minutes
resulted in the recruitment of RAR/ RXR, TDG and CBP to the same region of the promoter
(Figure 2.4 B-C). To confirm that TDG, RAR and CBP simultaneously occupy the Hic1 promoter,
chromatin was immunoprecipitated with an anti-RARα or anti-CBP antibody and the
immunoprecipitated material was subjected to an additional immunoprecipitation with an antiTDG specific antibody (ChIP-reChIP). These results indicate that on the Hic1 promoter, TDG
associates simultaneously with both RARα and CBP in response to RA. Additionally, as an
indicator of active transcription, treatment with RA is also associated with the accumulation of
phosphorylated RNA polymerase II (p-Pol II) and RXRα (Figure 2.4 D).
Co-transfection assays with various reporter fragments containing regions of the Hic1
promoter (Guerardel et al., 2001; Gue et al., 2004) revealed that the promoter fragments containing
the identified DR5 RARE sequence exhibited increased activity in the presence of constitutively
active Rarα-VP16 or Rxrα-VP16 (Figure 2.6 A). The ability of the DR5 RARE to function as an
RAR-responsive element in a heterologous promoter was also tested. A multimerized version of
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Figure 2. 2 Hic1 expression in developing limb buds
(A) Analysis of Hic1 and Rarβ expression in Cyp26b1 wild-type and null embryos. RNA was
isolated from the proximal limb bud (FL: fore-limb) or distal (paddle region; HL: hind-limb) of
the limb buds at the indicated times, and gene expression was normalized to 18sRNA. Significance
indicated as *, p < 0.05; **, p < 0.01; #, p < 0.001.
(B) Comparison of Hic1 expression to RARE-LacZ reporter activity in the developing limb buds.
Whole-mount in situ hybridization was carried out to examine Hic1 expression and corresponding
RARE-LacZ limb buds were stained with X-gal.
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Figure 2. 3 HIC1 expression in MCF7 cells and purification of TDG.
(A) HIC1 expression in MCF7 breast cancer cells. Cultured MCF7 cells were transfected with
either control or TDG siRNA. After 48 hr, cells were treated with 1 µM EC23 for 24 hr. Proteins
were isolated and immunoblotting was performed with the indicated antibodies.
(B) Western blot of control and FLAG-tagged TDG HT1080 cell lines. Un-transfected or stably
transfected FLAG-tagged TDG HT1080 cells were grown to confluency, proteins extracts were
isolated and immunoblotting (IB) was performed with the indicated antibodies.
(C) Control and FLAG-TDG stable cell lines were treated with 1 µM RA for 90 min and then
treated with the Dithiobis[succinimidylpropionate] (DSP) crsosslinker for 30 min. Cells were
harvested and nuclear proteins isolated. Crosslinks were reversed by the addition of 100 mM DTT.
Proteins were separated by SDS-PAGE and immunoblotted with TDG antibody (1:3000).
(D) Immunopurification of TDG complexes. Un-transfected or stably transfected FLAG-tagged
TDG HT1080 cells were grown to confluency and then treated with 1 µM RA for 90 min and then
treated with the DSP crosslinker for 30 min. Proteins were isolated and immunoprecipitations (IP)
were performed using anti-FLAG Sepharose. The immune complexes were purified using antiFLAG Sepharose, crosslinks were reversed and immunoblotting was performed with the
antibodies shown on the left of the panel.
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Figure 2. 4 The Hic1 gene is a direct target for the RARα/TDG/CBP complex.
(A) Schematic of the murine Hic1 locus. The mouse Hic1 upstream regulatory region is shown
including Hic1 coding and non-coding exons which are shown as solid bars. The various regions
(RARE, TATA and Gene) are indicated at the bottom of the figure and the proximal RARE is
found approximately 650 bp upstream of the P0 promoter and is shown as a red triangle.
(B, C and D) ChIP analysis of the Hic1 locus. MEFs were treated with DMSO (vehicle) or RA (1
µM) for 90 min and ChIP or sequential ChIP (ChIP-reChIP) assays were performed with the
indicated antibodies. ChIPs were analyzed by qPCR with primers corresponding to specific regions
of the Hic1 gene (RARE, TATA or Gene) as indicated at the bottom of each graph. For qPCR IgG
control values were subtracted from the values using specific antibodies.
Significance indicated as *, p < 0.05; **, p < 0.01; n=3.
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the DR5 RARE along with a mutant form was generated and tested, and the wild-type version
showed a > 20-fold induction when co-transfected with an Rarα-VP16 expression construct
(Figure 2.6 B). Collectively, these findings indicate that Hic1 is a direct RAR target gene and that
RAR, CBP and TDG co-occupy the same region of the Hic 1 promoter following RA treatment
thus establishing a causal relationship between recruitment and Hic1 expression.
A second distal RARE was found approximately 22 kB downstream of the Hic1 locus,
between introns 14 and 15 of the Smg6 gene which is directly adjacent to Hic1 (Figure 2.5 A).
ChIP analysis of this site revealed that RARα, CBP and TDG also bind to this region in response
to RA treatment and that the abundance of these proteins was comparable to that of found on the
upstream Hic1 P0 promoter (Figure 2.5 B). Based on these results, we speculated that the proximal
and distal RARE containing regions might physically associate following RA induction.
Therefore, we developed a series of primers for chromosome conformation capture (3C) and using
the Hic1 RARE as bait, we assessed the formation of chromatin loops. Remarkably, we find that
chromatin surrounding the distal RARE within the Smg6 locus undergoes RA dependent looping
and interacts with the proximal RARE at the Hic1 locus (Figure 2.5 C). This finding suggests that
recruitment of the RARα complex could potentially facilitate the physical association between
these sites during Hic1 transcription.

2.2.2 Hic1 undergoes active demethylation in response to RA
Hypermethylation of the Hic1 P0 promoter is common in many cancers and contributes
towards its epigenetic silencing (Britschgi et al., 2008; Aggerholm et al., 2006; Fleuriel et al.,
2009; Britschgi et al., 2006). To assess the DNA methylation status at the Hic1 locus in response
to RA, initial experiments were performed using bisulfite conversion of the DNA spanning a 1.5
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kb region (Figure 2.7). Although the overall methylation of the locus decreased by approximately
25%, the region encompassing the RARE remained unmethylated in untreated and RA-treated
cells. However, we identified a 155 bp core CpG-rich region (Chr 11: 75,168,133 – 75,167,978)
within the Hic1 P0 promoter that undergoes rapid DNA demethylation in response to RA (Figure
2.8 A). This finding was further validated using both methyl and un-methyl specific PCR (MSP
and USP, respectively) targeting seven CpG’s within the P0 promoter that show the most
consistent methylation change in response to RA (Figure 8B). The rapidity of this response in
MEFs, and the observation that RA stimulation often arrests cells in G1 phase (Tang & Gudas,
2011; Dimberg and Oberg, 2003), suggests that demethylation involves an active mechanism that
is not dependent on multiple cell divisions.
Bisulphite sequencing is unable to distinguish between unmethylated cytosine, 5fC and
5caC. To identify CpG sites that undergo active demethylation in response to RA, we analyzed the
Hic1 P0 promoter by M.SssI-assisted bisulphite sequencing (MAB-seq). MAB-seq consists of pretreating genomic DNA with the bacterial methyltransferase enzyme M.SssI. The M.SssI treated
DNA is then treated with bisulphite which will convert 5fC and 5caC to thymine (T). However,
cytosine (C) is now protected as 5mC. Therefore, sequencing would indicate 5fC and 5caC as T,
whereas C/5mC/5hmC would be sequenced as C (Wu et al., 2014). The efficiency of M.SssI was
greater than 98% based on methylation of lambda phage DNA which lacks CpG methylation
(Figure 2.9). In control cells, conversion of 5mC to 5fC/5caC was negligible. Remarkably, a 3hour treatment with RA resulted in a combined increase of 5fC/5caC to 27.0 % (Figure 2.8 A). In
contrast, treatment with an RA antagonist (AGN194310) failed to cause a significant accumulation
of these
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Figure 2. 5 Formation of RA-dependent chromatin loops at the Hic1 locus
(A) Schematic of the murine Hic1 genomic region. The region downstream of Hic1 which
encompasses the 3’ region of the Smg6 gene is shown. Various exons are shown as solid bars and
the proximal and distal RAREs are shown as red triangles.
(B) ChIP analysis of the distal RARE. MEFs were treated with DMSO (vehicle) or 1 µM RA for
90 min and ChIP assays were performed with the indicated antibodies. ChIPs were analyzed by
qPCR with primers encompassing the distal RARE region of the Hic1 gene.
(C) Chromatin looping following RA treatment of MEFs. 3C analysis was carried out as described
in the Materials and Methods. To detect looping, various combinations of primer pairs were used
for PCR quantification following enzymatic digestion and verified by gel electrophoresis. A
product was detected only when “Bait” and “Z” primers were used indicating that looping only
occurs in the region containing the two RARES.
Significance is indicated as *, p < 0.05; **, p < 0.01; #, p < 0.001. n=3.
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Figure 2. 6 The Hic1 gene contains a bona fide DR5 RARE
(A) Identification of a conserved DR5 RARE in Hic1 gene and activation of promoter fragments
containing this element with constitutively active versions of Rara and Rxra, Rara-VP16 and RxraVP16, respectively.
(B) multimerization (3) of the Hic1 RARE (1ab), but not a mutant (m1 ab) form confers RaraVP16 reporter gene inducibility on a heterologous promoter.
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metabolites (Figure 2.10 A). Overall, these results suggest that active demethylation at the Hic1
locus is RA-dependent and involves oxidation of 5mC to 5fC/ 5caC.
To determine if DNMTs are involved in regulating the Hic1 P0 promoter methylation, we
investigated the role of de novo methyltransferase DNMT3a. In control cells, DNMT3a is enriched
at the Hic1 proximal RARE and its abundance is reduced upon RA treatment (Figure 2.8 C).
Knockdown of DNMT3A using siRNA resulted in demethylation of the P0 promoter (Figure 8D
and 10B) and upregulation of HIC1 expression in the absence of RA (Figure 2.8 E and 2.10 C).
MAB-seq analysis indicated a 2.2-fold increase in 5fC/5caC when DNMT3A is knocked down in
MEFs (Figure 2.10 D). These observations suggest that methylation of the Hic1 P0 promoter is
dynamic and that DNMT3a is necessary for maintaining RA-dependent transcriptional repression
of Hic1.
2.2.3 Recruitment of CBP and active demethylation are TDG dependent
The above results indicate that RA-dependent regulation of Hic1 involves the recruitment
of an RAR/CBP/TDG complex which initiates active demethylation at the P0 promoter of Hic1.
To examine a more direct requirement for TDG in this mechanism, we generated Tdg f/f; UBCcre/ERT2 mice. To drive widespread deletion of Tdg in adult mice, the UBC-CreERT2 line was
used. These mice contain floxed Tdg alleles along with the ubiquitin C promoter driving the
tamoxifen (TAM) regulated Cre recombinase. This strategy circumvents embryonic lethality and
allows conditional deletion of Tdg globally in a temporal manner in response to TAM (Ruzankina
et al., 2007) (Figure 2.11 A-C). MEFs were prepared from this mouse line and incubated with or
without TAM prior to treatment with RA. In control cells, Hic1 levels are minimally detectable
and RA treatment caused a pronounced induction of both protein and mRNA levels (Figure 2.12
A and 2.12 B). In contrast, when grown in the presence of TAM, Tdg is efficiently deleted and
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RA-dependent expression of Hic1 is inhibited. TAM pre-treatment had no impact on Hic1
induction, suggesting that the loss of its expression may be attributable to Tdg deletion (Figure
2.11 D). Furthermore, transient overexpression of TDG resulted in partial restoration of HIC1
expresssion in TDG-deleted MEFs (Figure 2.11 E).
ChIP analysis confirmed that TDG and CBP are no longer recruited to the Hic1 locus in
Tdg deleted MEFs (Figure 2.12 C). We also examined the recruitment of TET1 and TET2 proteins
as recent studies have shown that they interact physically with TDG and TET1 and TDG co-occupy
similar genomic regions in ES cells (Weber et al., 2016; Neri et al., 2015). Treatment with RA
resulted in a dramatic increase in TET2 recruitment to the Hic1 locus that was transient and
decreased to basal levels by 3 hrs. Importantly, the transient increase in TET2 recruitment was
inhibited in Tdg knockout MEFS (Figure 2.12 D). The recruitment of TET1 was also increased in
response to RA. Remarkably, TET1 recruitment was not TDG dependent and increased further in
TDG knockout MEFs. This suggests that the mechanism of recruitment for TET1 and TET2 is
different. To assess if TDG is required for RA dependent active DNA demethylation of the Hic1
P0 promoter, we performed MAB-seq analysis in wild-type and Tdg deleted MEFs following a 3hour RA treatment (Figure 2.12 E). In untreated cells, a 4-6-fold increase in 5fC/5caC was
observed upon Tdg deletion. This is consistent with previous models showing that under steady
state conditions, loss of Tdg causes an accumulation of 5mC derivatives (Kohli & Zhang, 2013;
Shen et al., 2013; Ito et al., 2011). Surprisingly, the accumulation of 5fC/5caC was not significantly
different between wild-type and Tdg knockout MEFs upon RA treatment, suggesting that the RA
driven conversion of 5mC to 5fC/5caC is not evident upon Tdg deletion at this time point.
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Figure 2. 7 Bisulfite sequencing of the Hic1 locus.
(A) bisulfite sequencing of 36 CpG sites surrounding the RARE at Hic1 locus reveals a 2.7 %
methylation in the untreated state.
(B) Bisulfite sequencing of 58 CpG sites downstream of the RARE reveals RA dependent DNA
demethylation at the locus, and particularly within the P0 promoter.
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Figure 2. 8 RA dependent active demethylation at the Hic1 promoter.
(A) DNA methylation analysis of the Hic1 P0 promoter. MEFs were treated with DMSO (vehicle)
or RA for 3 hrs. DNA was extracted, and either the DNA was treated with bisulphite alone and
then sequenced (Bisulfite Sequencing), or the isolated DNA was treated sequentially with M.SssI
and then bisulfite (MAB-seq) followed by sequencing of the P0 promoter region of the Hic1 gene.
Shown are a representative result from three independent experiments.
(B) Samples were treated with bisulfite and then analyzed by PCR using specific primers
recognizing the methylated (MSP) or unmethylated (USP) region contained within the P0
promoter.
(C) Loss of DNMT3A occupancy at the proximal RARE. MEFs were treated with DMSO (vehicle)
or 1 µM RA for 90 min and ChIP assays were performed with a DNMT3A antibody. ChIPs were
analyzed by qPCR with primers corresponding to the proximal RARE region of the Hic1 gene.
(D) Methylation-specific PCR of the Hic1 promoter. MEFs were transfected with the indicated
siRNAs. Cells were then treated with DMSO (vehicle) or RA for 90 min. DNA was extracted and
the core CpG region of the Hic1 P0 promoter was analyzed by methylation-specific PCR using
primers recognizing the methylated sequence.
(E) Western blot analysis of HIC1. MEFs were transfected with the indicated siRNAs. Proteins
were extracted and immunoblotting (IB) was performed with the indicated antibodies.
*, p < 0.05; **, p < 0.01; #, p < 0.001; NS: not significant.

61

62

Figure 2. 9 Optimization of the M.SssI enzyme for the methylase-assisted bisulfite
sequencing technique.
Treatment of the λ DNA, which completely lacks DNA methylation, with the M. SssI methylase
enzyme leads to efficient methylation of DNA.
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Figure 2. 10 MABseq analysis at the Hic1 P0 promoter
(A) Treatment of MEFs with an RA antagonist. MEFs were treated with vehicle (DMSO) or 1
µM AGN194310 for 3 hrs and then MABseq was performed as described in Materials and
Methods.
(B) Methylation-specific PCR (MSP) of the Hic1 P0 promoter. MEFs were transfected with the
indicated siRNAs. DNA was extracted and the core CpG region of the Hic1 P0 promoter was
analyzed by MSP using primers recognizing the methylated sequence.

Region 8 bisulfite

sequencing primers (i.e. contain no CpG sites) were used for normalizing the DNA loading.
(C) MEFs were transfected with control siRNA or siRNA targeting DNMT3A. After 48 hrs,
proteins were extracted and immunoblotting was performed with the indicated antibodies.
(D) MEFs were transfected with siControl or siDNMT3A, and after 48 hrs DNA was isolated.
MAB-seq was then performed by treating the isolated DNA sequentially with M.SssI and then
bisulphite as described in Materials and Methods. The P0 promoter region of the Hic1 gene was
then analyzed by conventional sequencing.
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Therefore, we performed MAB-seq at different time points following RA treatment (Figure 2.12
F). In the presence of TDG, 5fC/5caC intermediates accumulate in response to RA and reach a
peak of 22% at 6 hours (Figure 2.12 F). This finding shows that the accumulation of 5mC
derivatives in response to RA is not significantly affected upon Tdg deletion, but their subsequent
removal is blocked.
We also examined the accumulation of 5fC/5caC at the Rarβ gene. Like Hic1, the Rarβ
gene contains a consensus RARE upstream of a CpG island within its promoter and has been
previously shown to be an RAR target that is induced in response to RA (May et al., 2010).
Treatment with RA for 90 minutes resulted in the recruitment of TDG, TET1 and 2 to the Rarα
RARE within its promoter (Figure 2.13 A). Importantly, MAB-seq analysis resulted in a six-fold
increase in 5fC/5caC in response to 3 hr RA treatment (Figure 2.13 B).
Collectively, these findings suggest that Tdg is required for promoting RAR complex
stability as well as active DNA demethylation at the Hic1 locus, as well as other RAR-dependent
genes.

2.2.4 Tdg deletion in vivo causes Hic1 silencing
Based on the observation that TDG plays a role in RA-dependent Hic1 regulation, we
speculated that Tdg deletion in mice would also affect the induction of HIC1 protein in vivo. In
order to test the efficiency of cre-ERT2 recombinase activation, adult UBC-cre/ERT2;Tdgfl/fl and
Tdgfl/fl mice (8 weeks) were treated once/day for 5 days with TAM by intraperitoneal injection.
After 4 weeks, post-TAM treatment various tissues were isolated and TDG expression was
examined. TDG expression was reduced in all tissues examined (Figure 2.11 F). In tissues, such
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as spleen and thymus there was a dramatic loss in HIC1 expression (Figure 2.14 A and data not
shown). Importantly, the Hic1 gene from UBC-cre/ERT2; Tdgfl/fl mice is silenced and the Hic1 P0
promoter is entirely hypermethylated compared to wild-type mice (Figure 2.14 B).
These results strongly suggest that in the absence of active demethylation is disrupted and
the Hic1 locus develops a vulnerability to DNA hypermethylation as has been found in many
cancers.

2. 3 Discussion
The transcriptional repressor HIC1 is located at 17p13.3, a region that is often deleted or
hypermethylated (and silenced) in human cancers (Guerardel et al., 2001; Fleuriel et al., 2009).
Hypermethylation of the HIC1 locus has been frequently observed in a variety of tumors, including
breast, brain, and colon cancers. Consistent with these observations, Hic1 heterologous mice
exhibit an increased tumor burden and develop many different malignant tumors, including a
predominance of epithelial cancers, sarcomas and lymphomas (Mohammad et al., 2011).
Importantly, bisulphite sequencing of all of these tumors indicates that the remaining wild-type
Hic1 allele undergoes epigenetic silencing marked by DNA methylation (Briggs et al., 2008).
Despite the importance of HIC1 as a tumor suppressor, the mechanism regulating its expression is
poorly understood. Previous work has shown that HIC1 is induced by RA during granulocyte
differentiation (Britschgi et al., 2008). Herein we establish an important link between RA signaling
and transcriptional activation of the Hic1 gene in vitro and in vivo. We have found that
transcriptional silencing of Hic1 is mediated, in part, by DNMT3a, which is required to maintain
the methylation status of the P0 promoter. We show for the first time that activation of the RAR/
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Figure 2. 11 Conditional deletion of TDG
(A) Schematic diagram of the mouse TDG genomic structure showing the location of the loxp sites
(B– C) Treatment of Tdg fl/fl and Tdg fl/fl; UB-cre/ERT2+ MEFs with 100 nM 4-hydroxytamoxifen
causes an efficient recombination of Tdg exon 2 and loss of TDG at the protein level.
(D) The treatment of MEFs with 100 nM 4-hydroxytamoxifen does not affect the expression of
HIC1 by EC23.
(E) Re-introduction of TDG in Tdg KO MEFs results in partial rescue of HIC1 expression. The
cre-ERT2 mediated depletion of TDG protein was performed using 4-OH-TAM as described in
Material and Methods. Tdg KO MEFs were transfected with a plasmid containing FLAG-TDG
under the control of the CMV promoter and allowed to grow for 2 days prior to treatment with
EC23. The lysates were prepared 24 hour following EC23 treatment and western blot performed
using the indicated antibodies (TDG, 3000X; Vinculin, 10000X; mHIC1, 5000X).
(F) Conditional deletion of TDG in adult mice. Intraperitoneal injection of 15 mg tamoxifen over
a 5-day period in adult (8 weeks old) Tdg fl/fl and Tdg fl/fl; UB-cre/ERT2+ mice reveals an efficient
knockdown of TDG at the protein level. Tissues were harvested from these mice 4 weeks after the
last tamoxifen injection, protein extracts were prepared and analyzed by immunoblotting using
anti-TDG antibody (1:3000).
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Figure 2. 12 Transcriptional activation of Hic1 in response to RA is TDG dependent.
(A) MEFs were incubated in the presence or absence of 4-hydroxytamoxifen (4-OH-TAM) for 48
hrs. and then treated with EC23 for 24 hrs. Proteins were isolated and immunoblotting (IB) was
performed with the indicated antibodies.
(B) MEFs were treated with DMSO (vehicle) or 1 µM RA. RNA was extracted and analyzed by
qPCR.
(C) Control or Tdg knockout (KO) MEFs were treated as described in (B) and ChIPs were
performed using either a TDG (left) or CBP-specific antibody (right). Products were analyzed by
qPCR with primers encompassing the Hic1 P0 promoter.
(D) Wildtype and Tdg knockout MEFs were treated with DMSO (vehicle) or 1 µM RA for various
time periods as shown. ChIPs were performed using either a TET2 or TET1 specific antibody.
Products were analyzed by qPCR with primers encompassing the Hic1 P0 promoter.
(E) Wildtype and Tdg knockout MEFs were treated with DMSO (vehicle) or 1 µM RA for 3 hrs.
DNA was isolated and M.SssI-assisted bisulphite sequencing (MAB-seq) was performed by
treating the isolated DNA sequentially with M.SssI and then bisulphite as described in Materials
and Methods. The P0 promoter region of the Hic1 gene was then analyzed by conventional sanger
sequencing.
(F) Time course of 5fC/5caC accumulation in MEFs. Wildtype and Tdg knockout MEFs were
treated with DMSO (vehicle) or 1 µM RA. DNA was isolated and MAB-seq was performed as
described in (E). The P0 promoter region of the Hic1 gene was then analyzed by conventional
sanger sequencing. Where indicated *, p < 0.05; **, p < 0.01, NS: not significant.
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Figure 2. 13 RA-dependent active demethylation of the Rarβ gene
(A) ChIP analysis of the Rarβ promoter. In the schematic representation of Rarβ gene, the major
exon is shown as a solid bar and the RARE is shown as a red triangle upstream of a CpG island.
MEFs were treated with DMSO (vehicle) or 1 µM RA for 90 min and ChIP assays were performed
with the indicated antibodies. ChIPs were analyzed by qPCR with primers encompassing the
RARE region of the Rarβ promoter.
(B) RA dependent active demethylation of the Rarβ gene. MEFs were treated with DMSO
(vehicle) or RA for 3hrs. DNA was isolated and MAB-seq was performed by treating the isolated
DNA sequentially with M.SssI and then bisulphite as described in Materials and Methods. The
CpG island encompassing the RARE, promoter and exonic regions of the Rarβ gene were then
sequenced
Where indicated *, p < 0.05; **, p < 0.01, NS: not significant.
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RXRα pathway displaces DNMT3A, triggering active demethylation of the P0 promoter.
Furthermore, this involves recruitment of TET proteins and accumulation of 5fC/5caC metabolites.
Importantly, we have generated a new conditional mouse model to demonstrate that the expression
of Hic1, and accumulation and subsequent removal of 5fC/5caC, are TDG dependent. Loss of
TDG in vivo leads to Hic1 silencing that correlates with DNA hypermethylation of the Hic1
promoter. These results highlight the importance of TDG in signal dependent DNA
methylation/demethylation events and highlight an important role for RAR/RXR in mediating
targetted active DNA demethylation

2.3.1 Involvement of 5fC/5caC in RA dependent Active Demethylation
MAB-seq is a novel technique that allows the quantitative mapping of both 5fC and 5caC
and is ideal for studying DNA methylation dynamics at specific loci because it does not require
subtractive analysis of two sequences (Neri et al., 2015). Our data indicates that in wild-type MEFs,
the accumulation of 5fC/5caC metabolites at the Hic1 P0 promoter is time dependent, peaking at
approximately 90 minutes after RA treatment and then declining to near basal levels by 6 hr. In
contrast, upon the conditional deletion of Tdg, 5fC/5caC metabolites continue to accumulate
suggesting that their excision rate is decreased with a concomitant loss of DNA demethylation at
the locus and downregulation of the Hic1 transcript. TET2 is also recruited to the Hic1 promoter
upon RA treatment and correlates with a loss of DNA methylation and upregulation of 5fC/5caC
at the P0 promoter. In the absence of TDG, accumulation of TET2 is diminished suggesting that
TDG is required for recruitment and anchoring of TET2 at sites of active DNA demethylation
(Muller et al., 2014). In contrast, TET1 recruitment is maintained and its levels increase further
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Figure 2. 14 Hic1 expression is TDG dependent in vivo
(A) Tdffl/fl (wild-type) or UBC-CreERT2; Tdgfl/fl (Tdg KO) mice were injected with 4-OH-TAM
for 5 days and allowed to recover for 2 weeks. Spleen tissues were removed, and proteins were
isolated and analyzed by immunoblotting with the indicated antibodies.
(B) Spleens from Tdgfl/fl (control) or UBC-creERT2; Tdgfl/fl mice were removed, and DNA isolated
and analyzed by bisulphite sequencing as described in Materials and Methods. The mouse B cellspecific gene product (MB-1) was used as control. The analysis is representative of 3 independent
experiments.

76

77

when TDG is deleted. The reason for these differences between TET1 and TET2 are not entirely
clear. Although TET isoforms 1 and 2 are capable of oxidizing 5mC, into 5hmC, 5fC and 5caC,
they differ structurally in terms of their domain architecture as well as tissue specificity. TET1
contains an N-terminal CXXC domain which is notably absent in TET2. The CXXC domain is a
novel DNA binding motif that binds dinucleotide CpGs as wells as 5caC with high affinity
suggesting that it is most likely involved in targeting the enzyme to specific genomic regions (Jin
et al., 2016). This could explain why 5fC/5caC continue to accumulate despite the loss of TET2.
Overall, these findings indicate that TDG functions downstream of 5fC/ 5caC formation and that
its dual catalytic and scaffolding activities are essential for Hic1 transcription.
MABseq has previously shown that 5fC/5caC metabolites become enriched near the
transcription start sites (TSS) of many actively transcribed genes in ES cells and in some contexts,
may serve as an indicator of 5mC demethylation (Neri et al., 2015). However, recent studies have
identified additional functions for 5fC/5caC suggesting a potential role of these cytosine
derivatives beyond transient intermediates. Reader proteins that specifically bind 5fC/5caC in vitro
have been identified (Spruijt et al., 2013). Furthermore, the introduction of 5fC/5caC within a
dsDNA template causes transcriptional pausing and interferes with transcription by RNA pol II
during transcriptional elongation in vitro (Wang et al., 2015). This suggests that 5fC/5caC
metabolites may be important for fine tuning the elongation of specific genes and thereby affect
gene expression. Furthermore, TDG interacts with RARα, as well as other coregulators such as
CBP/p300. It is conceivable that TDG bound 5fC/5caC may play a functional role in targeting
proteins in order to modulate transcriptional elongation.
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2.3.2 Accumulation of 5fC/5caC may predispose DNA to subsequent hypermethylation
Conditional deletion of Tdg in vivo causes a loss of HIC1 expression. Remarkably,
bisulphite analysis in spleen from Tdg knockout mice indicated that the Hic1 P0 promoter is
entirely hypermethylated in vivo and HIC1 is not expressed. This contrasts to our finding in MEFs
showing that Tdg deletion causes 5fC/5caC metabolites to accumulate in a time-dependent manner.
This suggests that Tdg deletion may cause an accumulation of 5fC/5caC, and in combination with
the loss of TDG scaffolding activity, predisposes this site to subsequent DNA hypermethylation.
Furthermore, 5fC/5caC cannot be maintained by DNMT1, hence, they would undergo passive
dilution upon subsequent cell divisions. This would provide access to de novo DNA
methyltransferases for subsequent hypermethylation of these sites. This model is supported by a
recent study indicating that sites of 5fC accumulation upon Tdg knockdown are specifically
targeted for DNA hypermethylation following differentiation (Raiber et al., 2012).

2.3.3 Implications of Active Demethylation in Retinoic Acid Signaling Events
Although TDG has been shown to function as a scaffolding protein at several RA
dependent genes, our study represents the first demonstration that RA triggers active DNA
demethylation and has important implications to our general understanding of the function of the
RA signaling pathway. Previous studies have indicated that DNA methylation is lost upon the
stimulation of certain RA responsive genes, such as Rarβ and Cyp2A1 (Le May et al., 2010).
However, the involvement of TETs and the generation of 5mC oxidation products was not
established. The finding that Hic1 and Rarβ genes are regulated by a similar mechanism represents
the first line of evidence for retinoid signaling in 5mC oxidation by TET/TDG pathway involving
a loss of 5mC and generation of 5fC/5caC metabolites.
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Retinoid signaling is known to be compromised in many cancers, and DNA
hypermethylation of retinoid target genes plays a major role in loss of sensitivity to RA (Farias et
al., 2002; Narayan et al., 2003). Furthermore, retinoids often exhibit anti-proliferative activities
and in many systems RA-induced growth arrest is associated with increased cell differentiation or
apoptosis (Wales et al., 1995). Hic1 is hypermethylated in a large number of diverse cancers, and
it will be of interest to determine if aberrant RA signaling at least in part underlies silencing of
HIC1 in cancer. In this regard, therapeutic strategies aimed at re-activating HIC1 expression may
prove useful for modifying tumour initiation, growth and progression.
Herein, we have identified Hic1 as a novel RA target gene and show that active DNA
demethylation is an essential step in gene transcription of Hic1 in response to RA. We find that
this process requires RA-dependent 5mC oxidation, which is mediated by TET proteins. Our data
suggests that TDG facilitates 5fC / 5caC turnover in MEFs, and that deletion of Tdg can predispose
genes to hypermethylation in vivo. These findings highlight the expanding role of TDG and active
demethylation in epigenetic regulation, and further identify important molecular mechanisms that
may be targeted by oncogenic processes.

2.4 Experimental Procedures
2.4.1 Mouse Protocol
All mouse experiments were done in compliance with the Institutional Animal Care and
Use Committee guidelines at London Regional Cancer Center at Western University and the
University of British Columbia. For the conditional deletion of Tdg, Tdg fl/fl mice were bred with
UBC-cre/ERT2 mice to generate UBC-cre/ERT2; Tdg fl/fl mice. Subsequently, adult (8 weeks old)
UBC-cre/ERT2; Tdg fl/fl and litter matched Tdg fl/fl controls were intraperitoneally injected with 3
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mg TAM daily for 5 days. To assess cre-ERT2 efficiency and HIC1 expression, the mice were
euthanized 4 weeks after TAM injections, tissues were harvested, lysed using RIPA buffer and
western blotting performed using anti-TDG-antibody.

2.4.2 Cell Culture and Transfection
Embryonic age (E) 17.5 MEFs were isolated from Tdg fl/fl or Tdg fl/fl; UB-cre/ERT2+ mice
as previously described (Jozefczuk et al. 2012). To induce deletion, the Tdg

fl/fl

UBC-cre/ERT2

MEFs were treated with 100 nM 4-hydroxytamoxifen for 48 hours, and then incubated with
DMEM for 48 hours prior to experimentation. For experiments involving treatments, cells were
grown to confluency in charcoal stripped supplemented media for 72 hours, before being
challenged with DMSO (Vehicle), 1 μM RA, EC23, or the RAR antagonist AGN194310 (4310).
Primary limb mesenchymal cultures (PLM) were established as previously described
(Underhill et al., 2014) and treated with ketoconazole (2 µM), BMP4 (20 ng/ml), 4310 (100 nM),
ATRA (100 nM) or vehicle control (DMSO). PLM cultures from Cyp26b1 wild-type and null
embryos were generated as previously described (Dranse et al. 2011). For transfection, reporter
plasmids containing various portions of the Hic1 promoter were transfected into PLM cultures as
previously described (Underhill et al., 2014) along with expression plasmids for Rarα-VP16 and
Rxra-VP16 (Underhill et al. 1994). To normalize for transfection efficiency, all transfections
included the control vector phRL. Forty-eight hrs post transfection, cultures were lysed in passive
lysis buffer and firefly renilla luciferase was measured using the dual luciferase reporter assay
system (Promega) according to the manufacturer’s guidelines. Luciferase activity is shown as
relative light units (RLU) which is generated by firefly luciferase activity/ renilla luciferase
activity.
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For siRNA mediated knockdowns, the cells were incubated with PepMute (SignaGen
laboratories) as per manufacturer guidelines. 20 µM concentration of respective siRNA’s were
utilized for transient knockdowns. The cells were incubated with siRNA and PePmute reagent for
48 hours and then media was changed, or lysates prepared depending on the experiment.

2.4.3 RNA extraction, reverse transcription polymerase chain reaction and real-time
polymerase chain reaction
Total RNA was extracted using an RNA extraction kit (Qiagen). cDNA was synthesized
using the Applied Biosystems Reverse Transcription Kit . The mRNA was reverse-transcribed for
10 min at 25 oC, followed by incubation at 37o C. Quantitative PCRs (qPCRs) were performed
using a Taqman or SYBR Green-detection system (Applied Biosystems) and transcript abundance
was normalized to 18s rRNA.

2.4.4 Chromatin Immunoprecipitation (ChIP)
ChIP and ChIP-reChIP assays were performed as previously described (Thillainadesan et
al. 2012).

2.4.5 Bisulfite sequencing and quantitative PCR
MEFs were grown to approximately 90 % confluency in charcoal stripped conditions and
then treated with 1 µM RA for 3 hours. Cells were then harvested and DNA was extracted using
the Sigma genomic DNA extraction kit. Approximately 1 μg of DNA was used for bisulfite
conversion using the Epitect Bisulphite Kit (Qiagen) according to the manufacturer’s instructions.
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For methyl-specific or un-methyl specific PCR, the bisulfite converted DNA was used in
conjunction with methyl-specific or un-methyl specific primers, respectively, and SYBR Green
Master Mix was used for qPCR.

2.4.6 MAB-SEQ
Mab-seq was performed as described (Wu et al. 2014). Briefly, 1 μg of genomic DNA was
treated with 4 U of M.SssI (NEB) in a 20 μl reaction containing 160 mM SAM for 2 hrs. The
reaction was then supplemented with an additional 4 U of M.SssI and 160 mM SAM for another 4
hours. DNA was purified by Phenyl: chloroform: isoamyl (PCI) followed by ethanol precipitation
after each round of treatment. This was repeated an additional three times. The methylated DNA
template was then bisulfite converted, and specific regions were PCR amplified, cloned into TA
vector and sequenced.

2.4.7 Generation of a FLAG-TDG expressing HT1080 cell line
The FLAG-TDG expressing HT1080 cell line was generated using the FLP-IN system
(Thermo Fisher) per the manufacturer’s instructions. An HT1080 fibrosarcoma cell line containing
a single integrated Flp Recombination Target (Frt) site was grown to roughly 70–80 % confluency.
The cells were then co-transfected with a plasmid containing a Flag-TDG cDNA driven by a CMV
promoter and containing an Frt site, and a second plasmid containing FLP recombinase cDNA,
respectively. After 48 hours, HT1080 cells were grown in the presence of 175 µg/ml hygromycin
containing media to select for the cells with integration of the FLAG-TDG gene. The resulting
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resistant colonies were expanded, extracts prepared and assessed for expression of the FLAG-TDG
protein by immunoblotting using anti-FLAG antibody (1:300) or anti-TDG antibody (1:3000).

2.4.8 Reversible Crosslink Immunoprecipitation (ReCLIP) Protocol
The ReCLIP protocol was performed as previously described (Smith et al. 2011). Briefly
cells were incubated with 20 mM DSP in PBS for 30 minutes at room temperature. The reaction
was quenched with a 125 mM glycine solution and cell extracts were prepared with a lysis buffer
consisting of 50 mM Tris (pH 8.0), 0.3M KCl, 0.1% NP40 and 0.5 mM EDTA.
Immunoprecipitations were then performed using anti-FLAG Sepharose per the manufacturer’s
instructions (Sigma). To reverse the crosslinks, the protein lysates were incubated with 100 mM
DTT for 15 minutes at 100oC prior to western blotting

2.4.9 Chromosome Conformational Capture (3C) Assay
The 3C assay ws performed as previously described with minor modifications (Zuchegna
et al. 2014). Briefly, 2.5 x106 cells were crosslinked using 1 % formaldehyde in PBS buffer at
room temperature with shaking. The reaction was quenched with 125 mM glycine, and the fixed
cells were washed twice and then harvested using 1 ml of ice cold PBS. Harvested cells were spun
down at 250g for 10 minutes and then incubated in lysis buffer I (10 mM Tris-HCl [pH 8.0], 10
mM NaCl, 0.2 % NP40, and protease inhibitors), homogenized, and centrifuged at 450g for 15
minutes. The pelleted nuclei were washed using buffer I (1x restriction digest buffer), and then resuspended in 1 x restriction buffer. SDS was added to a final concentration of 0.1% and the cells
were incubated at 65 oC for 10 minutes with shaking to lyse the nuclei. Triton X-100 was added to
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the final concentration of 1 % to quench the SDS and then 100 U of NcoI was added and incubated
overnight at 37 oC with rotation. SDS was added to a concentration of 1 % and incubated at 65 oC
for 30 minutes with shaking, and then placed on ice and 1 ml of 1x ligation buffer containing 1%
Triton X-100 was added. The reactions were equilibrated to 16 oC and 50 U of T4 DNA ligase was
added and incubated overnight. The following day, 300 μg of proteinase K was added to each
reaction and then incubated at 65 oC overnight. The DNA was then purified using phenol:
chloroform: isoymyl (PCI) and ethanol precipitated. Samples were dissolved in 30 μl of TrisEDTA buffer (pH 8.0). The efficiency of digestion was assessed by amplifying a fragment
spanning two NcoI (uncut) sites in different 3C DNA preparations.

2.4.10 Statistical Analysis
The data represented in ChIP, ChIP-reChIP, qPCR (for mRNA expression), methylspecific qPCR and 3C figures are representative of at least three independent biological replicates.
For the 3C experiment, the data from gel electrophoresis was assessed by the ImageJ software,
using the untreated lane for normalization. All western blots are representative of at least duplicate
experiments. Statistical analyses were performed using GraphPad Prism 5.0, employing the
Student’s t-test (2 groups), or ANOVA with Tukey post-hoc (3 groups or more). All p-values over
0.05 were deemed not significant. Significance is indicated as follows: *, p < 0.05; **, p < 0.01;
#, p < 0.001; NS, not significant.
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Table 2. 1 List of antibodies used in this chapter
Antibody

Species

Company

Catalogue No.

TDG mouse

Rabbit

Homemade

N/A

RARα

Rabbit

Santa Cruz

sc-551

CBP

Rabbit

Santa Cruz

sc-369

HIC1 mouse

Rabbit

Homemade

N/A

RNA pol II

Rabbit

Abcam

ab5131

RXRα

Rabbit

Santa Cruz

sc-553

Vinculin

Mouse

Sigma

V9264

DNMT3a

Rabbit

Santa Cruz

sc-20703

Tubulin

Mouse

Sigma

T 5168

TET1

Rabbit

Active Motif

61443

TET2

Rabbit

Abcam

ab124297

TDG human

Rabbit

Pierce

PA5-29140

HIC1 human

Rabbit

Sigma

HPA043372

RARβ

Rabbit

Santa Cruz

sc-552

Anti-Flag

Mouse

Sigma

F3165

Table 2. 2 List of ChIP primers used in this chapter
Primer Name Forward
RARE

Reverse

5’-ATCTGGTCCTCGTGCGCC-

5’-

3‘

CCGAGTCCTCTAGGGAAGACA3’
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TATA

5’-

5’-CATTCAGGGCCGAGAAGTT-

TCTTGCTCCCGTCTTCCTTA-

3‘

3‘
Gene Body

5’-

5’-

GGTGCATGACAACCTGCTAA- GGCCTCAACACTGTCAGTCA-3‘
3‘
Distal RARE

RARβ RARE

5’-TGTCCTTGCCTGCTCTGAC- 5’-CTGCCCACTTCTTCCTTTTC3’

3’

5’-

5’-CGGAGCAGCTCACTTCCTAC

GGGAGTTTTTAAGCGCTGTG-

-3’

3’

Table 2. 3 List of 3C primers used in this chapter
Primer Name Sequence
Bait

5’-CGCTTTCCGCACACTCTTATCT3‘

B

5’GCTACTCAGAGCTACTTTCCCAG-3‘

Z

5’TCTCTCCACCAGGCTTATTCCTCTC3‘
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Table 2. 4 List of bisulfite sequencing primers used in this chapter
Primer

Forward

Reverse

RARE

5’-GGGGTTTTAAGTGTTTTTTTTAGAG-3‘

5’-CCAATTCCTCCTCTAAACCC -3’

Region

5’-GTTTTATGTTTTTGATTAGTTGAGG-3‘

5’-TTTAACAAATTATCATACACCACC-

Name

3‘

5
Region

5’-GTTTTTTGTTTTTTTATTTGGG-3‘

4

5’CCTCAACTAATCAAAAACATAAAAC3‘

Region

5’-GTTATTAGGTTGTTGAAATTGGG -3’

5’-CCCAAATAAAAAAACAAAAAAC -3’

5’-GAGTTGGGGAAGAGATGTGGAG -3’

5’-CCAACCCCAAATACTCCTAAACAC -

6
Region

3’

8
RARβ

5’-

5’-

GTTAGATTGGTTGGGTTATTTGAAGGTTAG CATCCATACAATCAAACATAATCTCTC
-3’

-3’

MSP *

5’-TTCGGGTCGGGTCGGTCG -3’

5’-AAAACGCCTCCCGCCTCG -3’

USP **

5’-TTGGGTTGGGTTGGTTGG -3’

5’-AAAACACCTCCCACCTCA -3’

Lambda 5’-TTTGGGTTATGTAAGTTGATTTTATG -3’

5’- CACCCTACTTACTAAAATTTACACC

DNA

-3’

MB-1

5’-GGGATTAGTGGTGATGAATT -3’

5’CTCTAAAAACTTCTAAACCCCCTAAC 3’
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* MSP: Methyl-specific PCR
** USP: Un-methyl specific PCR

Table 2. 5 Sequence of siRNA’s used for transient knockdowns used in this chapter
Target

Type

Species

siRNA sequence

Company

Catalogue
No.

5’-GCAAGGAUCUGUCUAGUAA
TDG

Pooled Human and
mouse

-3’

Dharmacon

M-040666-

5’-CAAAGAAGAUGGCUGUUA -

01-0050

3’
5’-GAGUAAAGGUUAAGAACUU
-3’
5’-GAAGUGCAGUAUACAUUUG
-3’
DNMT3a

Pooled Human and

Not stated

Santa Cruz

sc-37757

Not stated

Dharmacon

D-001206-

Mouse
siControl

Pooled Human and
Mouse

13
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Chapter 3:

Thymine DNA Glycosylase is a tumor suppressor of liver malignancies
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3.1 Introduction
The methylation of cytosine at 5th carbon (5mC) is important in a variety of biological
processes including gene regulation, genomic imprinting, X chromosome inactivation and the
suppression of mobile genetic elements (Bestor and Bourc’his, 2004; Jaenisch and Bird, 2003).
This mark is faithfully reproduced over successive replication cycles by the maintenance DNA
methyltransferase 1 (DNMT1) protein, whereas, the de novo DNMTs (DNMT2, DNMT3a and
DNMT3b) can deposit novel methylation marks in a cell cycle independent manner (Wu and
Zhang, 2017). Recent studies have demonstrated that DNA methylation is dynamic and can be
removed via both passive and active processes. In passive DNA demethylation, the methylated
DNA is diluted over successive replication cycles resulting from deactivation of the 5mC
maintenance machinery. 5mC can also be metabolized and actively demethylated in response to
specific signals, independent of DNA replication. This process involves the Ten eleven
translocation (TET1-3) family of proteins as well as Thymine DNA Glycosylase (TDG).
In active DNA demethylation, the TET proteins recognize and successively oxidize 5mC
to 5-hydroxyethylcytosine (5-hmC), and then to 5-formylcytosine (5-fC) and 5-carboxylcytosine
(5caC) (Hassan et al., 2017; He et al., 2010; Ito et al., 2011; Piccolo and Fisher, 2014). The BER
protein Thymine DNA Glycosylase (TDG) plays an essential role in this process by catalyzing the
initial removal of 5-fC and 5-caC metabolites (Ito et al., 2011). This forms an apurinic (AP) site
and the combined actions of APE1, DNA pol β and XRCC1- DNA ligase IIIα complex
subsequently replace the AP site with an unmethylated cytosine. Interestingly, knockout studies
demonstrate that TDG is the only glycosylase in mammalian system that is necessary for
embryonic development (Cortazar et al, 2011; Cortellino et al., 2011) Knockout of TDG in mice
leads to embryonic lethality at a time point when the genome is undergoing epigenetic
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reprogramming.. This results in gene expression defects of numerous developmentally regulated
genes, as well as epigenetic instability involving DNA hypermethylation, the loss of active
chromatin marks and the accumulation of repressive marks (Cortázar et al., 2011; Cortellino et al.,
2011; Hajkova et al., 2010). TDG was also found to be essential for recruiting additional
coregulators such as the acetyltransferases CBP/p300, as well as other histone modifying proteins,
to target genes (Cortázar et al., 2011; Cortellino et al., 2011). Surprisingly, the loss of TDG did
not affect mutation frequency associated with classical base damage suggesting that its
contribution to base repair is unlikely to account for its essential function (Cortázar et al., 2011;
Cortellino et al., 2011). These findings are consistent with a central role of TDG in gene-specific
demethylation and epigenetic stability.
Despite the importance of TDG in active DNA demethylation and gene transcription, its
role in in post embryonic development and cellular homeostasis is unclear. Such studies could
provide considerable insight into the role of TDG in human diseases that involve widespread
transcriptional and epigenetic abnormalities, such as cancer. In cancer, the genome undergoes
widespread changes in the methylation landscape that is believed to contribute to disruption in cell
cycle control, angiogenesis and invasion. Specifically, global DNA hypomethylation of the
genome in combination with hypermethylation of the promoter regions of many tumor suppressor
genes represent hallmarks of all cancers (Jones and Baylin, 2002, 2007). These de novo changes
in the methylation landscape lead to aberrant regulation of a large set of genes that promote cellular
growth, angiogenesis and proliferation (Jones and Baylin, 2002, 2007). For example,
hypermethylation of tumor suppressor genes, such as p15ink4b and HIC1, contributes towards their
silencing and can also predispose genes to mutations via spontaneous deamination of 5methylcytosine to thymine (Shen and Laird, 2013).
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To determine the role of TDG in adult mice, we used an inducible Cre/Loxp system to
circumvent embryonic lethality. Herein, we demonstrate that global Tdg deletion in adult mice
leads to hepatocellular carcinoma (HCC) and hepatoblastoma (HB). Surprisingly, the onset of liver
cancer did not involve the cirrhotic/ fibrotic (NCF) pathway and was highly prevalent in male
mice. RNAseq analysis of livers from TDG deleted mice indicated a dysregulation in metabolism
and p75NTR signaling, and upregulation in several cancer relevant pathways (MAPK, HIPPO,
TGF) compared to livers from age matched control mice. Dysregulation in metabolism is
characteristic of non alcoholic fatty acid liver disease (NAFLD), a pathophysiological condition
which ultimately leads to HCC and is found predominantly in males (Hashimoto et al., 2009). In
combination with increased MAPK and HIPPO signaling cascades which promote liver cell
proliferation and growth, our study provides evidence that a loss or dysregulation of TDG could
potentially predispose mice to HCC through the NCF-NAFLD pathway of liver cancer.
3.2 Results
3.2.1 Generation of Tdg fl/-; UB-cre/ERT2+ mouse line
To circumvent embryonic lethality associated with embryonic TDG deletion and determine
its role in adult mice, a UBC-Cre-ERT2 transgenic mouse line was used. UBC-Cre-ERT2 contains
an inducible Cre-ERT2 under the control of the ubiquitin C promoter (UBC) which allows for
widespread expression of the Cre recombinase. The Cre-ERT2 is composed of Cre recombinase
fused with a mutant form of estrogen receptor, which is activated exclusively in the presence of
tamoxifen (TAM). This line was bred with a floxed conditional allele of Tdg targeting exon 2,
resulting in efficient deletion of TDG in the whole body.
Using this system, a Tdg fl/-;UB-Cre/ERT2+ mouse line was generated containing a single
integrated copy of the Cre-ERT2. To test the efficiency of recombination, Tdg fl/-;UB-Cre/ERT2+
mice (8 weeks of age) were treated once per day for 5 days with TAM by intraperitoneal injections
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(Figure 3.1 A, B). Four weeks after the final treatment, mice were euthanized, and a variety of
tissues were analyzed for TDG knockout by western blot. Efficient recombination of TDG was
observed in all tissues tested, including brain, liver, colon, spleen, lung, thymus and heart (Figure
3.1 E and data not shown). Mouse embryonic fibroblasts were also generated from these mice and
treated with 4-hydroxytamoxifen (4OH-TAM) for 72 hours prior to the assessment of TDG
deletion (Figure 3.1 C, D). Consistent with the in vivo findings, 4OH-TAM treatment resulted in
efficient deletion of Tdg exon 2 and a loss of TDG at the protein level.

3.2.2 Hepatocellular carcinoma in Tdg fl/-; UB-cre/ERT2+ mice
The treatment of 8-weeks old Tdg fl/-; UB-cre/ERT2+ (TDGKO) mice with TAM resulted in
efficient knockout of TDG in all tissues tested (Figure 3.1 E). These mice were compared to Tdg
fl/fl

mice (control) also treated with TAM at 8 weeks of age.
Over the course of aging, the TDGKO mice failed to display any obvious phenotype and

remained healthy. In contrast, knockout mouse models of CBP and TETs, which interact with TDG
and contribute towards its activity, display an immune related phenotype (Cimmino et al., 2015;
Kang-Decker et al., 2004). For instance, the embryonic deletion of TET1 and TET2 leads to the
development of B-cell lymphoma, whereas, CBP conditional deletion in mice causes T-cell
lymphomagenesis (Cimmino et al., 2015; Kang-Decker et al., 2004). Based on these findings, we
predicted that a dysregulation of TDG in the whole body would compromise the immune system
and promote B and/or T-cell malignancies. To determine alterations in the immune system upon
TDG knockdown, we performed immunostaining of cells from lymph nodes, spleen and/ or
thymus tissues from a cohort of control and TDGKO mice. The cells from these mice were costained with a pan-leukocyte marker (CD45), as well as antibodies specific for B (CD19) or Tcells (CD3, CD4, CD8). However, immunophenotyping of 4 month and endpoint mice failed to
106

detect any drastic changes in the total abundance of these cells (Figure 3.2 B-D). Although a slight
increase in B-cells was prevalent in the spleen and lymph node of endpoint TDGKO mice, it was
not comparable to the Tet1-/- model which displayed an approximately 4-fold increase in B-cell
population compared to wild-type mice. Therefore, we disregarded a potential involvement of
TDG in the immune system phenotype.
After approximately 20 months post-TAM injections, a significant number of TDGKO mice
began showing a drastic decrease in total body weight. Upon euthanasia of these TDGKO mice, we
observed an increased prevalence of hepatocellular carcinoma (HCC) compared to the control
cohort (n= 8, Gehan-Breslow-Wilcoxon test p < 0.0001) (Figure 3.3 A, B). Hematoxylin and eosin
staining (H&E) and immunohistochemistry of the tumor tissues with glutamine synthetase (GS),
which is a marker of HCC in humans and mice (Salleng et al., 2015), were positive for HCC
(Figure 3.3 C-L).
Reticulin is a type of connective tissue fiber and is composed of type III collagen secreted
by reticular cells. Reticulin staining assists in the assessment of hepatic plate architecture and
thickness. The reticulin stain is also is clinically used to diagnose HCC and differentiate it from
non-malignant lesions in the liver tissue. In general, absent or weak reticulin staining that indicates
a thickened trabeculae (> 3 cell thick) supports the presence of HCC (Bergman et al., 1997; NejakBowen and Monga, 2011). Trabeculae is composed of dense collagenous tissue that appears in the
form of a beam, strut or a rod anchoring different cells and/ or tissues within an organ. The reticulin
staining of TDGKO tumors indicated weak and /or thickened plate architecture (> 3 cell thick
trabeculae) compared to control mice (Figure 3.3 J-L, T-V), which supports the diagnosis of HCC
in mice. Interestingly, the pathology analysis indicated that HCC in TDGKO
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Figure 3. 1 Efficient deletion of Tdg ex vivo and in vivo.

(A) Schematic of the mouse TDG genomic structure showing the location of the loxp sites.
(B) Schematic of the experimental mouse model and conditions used in this study.
(C-D) Treatment of Tdg

fl/fl

and Tdg fl/-; UB-cre/ERT2+ MEFs with 100 nM 4-hydroxytamoxifen

causes efficient recombination of Tdg exon 2 and loss of TDG at the protein level.
(E) Conditional deletion of TDG in adult mice. Intraperitoneal injection of 15 mg tamoxifen over
a 5-day period in 8-week old Tdg fl/fl and Tdg fl/-; UB-cre/ERT2+ mice causes efficient knockdown
of TDG at the protein level. Tissues were harvested from these mice 4 weeks after the last
tamoxifen injection, protein extracts were prepared and analyzed by immunoblotting using antiTDG antibody (1:3000).
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mice originated independent of fibrosis or cirrhosis since all the tissues examined failed to show
any signs of inflammaiton induced scarring which is indicative of liver damage.

3.2.3 Hepatoblastoma occurs in Tdg knockout mice with pre-existing HCC
Hepatoblastoma (HB) is a poorly differentiated and primitive hepatic tumor, which is
known to originate from immature fetal liver cells and primarily affects children from infancy to
3 years of age (Bhusari et al., 2015). In mice, however, HB is known to occur in a background of
preexisting HCC, with an onset of HB being associated with increased prevelance of HCC (Bhusari
et al., 2015; Turusov et al., 2002). In the TDGKO mouse model, a few mice presented both HCC
and HB (Figure 3.3 M – V), which was found to be negative for the GS stain (Figure 3.3 S). This
was to be expected since GS is an HCC specific stain (Salleng et al., 2015), which distinguishes it
from other liver abnormalities, such as hepatic adenoma and HB. However, the earliest case of
hepatoma formation was observed in a 19 month old TDGKO mice (17 months post TAM), which
displayed an overall normal liver with two tumor foci (Figure 3.3 C). These tumor foci were
positive for the GS stain (Figure 3.3 C, H, I) and displayed significantly reduced reticulin staining
pattern (Figure 3.3 K, L) compared to the adjacent normal liver (Figure 3.3 G, J), which is
consistent with HCC. In addition, HB was found exclusively in the presence of advanced HCC in
aged TDGKO mice (> 2 years old). These observations, in addition to evidence from previous
studies (Bhusari et al., 2015; Turusov et al., 2002), led us to conclude that the HB in our mice
originated from a pre-existing and well developed HCC.
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Figure 3. 2 Conditional deletion of TDG does not demonstrate an immune-related
phenotype

(A) Genetic crosses of Tdg+/- and Tdg

fl/fl

; UB-cre/ERT2+ mice generate Tdg

fl/-

; UB-cre/ERT2+

genotype and follow Mendelian ratios
(B-D) Conditional deletion of TDG in adult mice followed by immunophenotyping using
antibodies specific for the pan-leukocyte marker (CD45), B-cells (CD19), or T-cells (CD3, CD4
and CD8) in the spleen, thymus and/or lymph node tissue. The immunophenotyping was
performed in the spleen tissue of 4-month old and end-point mice (D), thymus tissue of mice that
are 4-month post TAM (E), and the lymph node of endpoint mice (F).
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Figure 3. 3 Loss of TDG predisposes mice to a high prevalence of hepatocellular carcinoma
(HCC) and hepatoblastoma (HB).

(A) Tdg knockout mice develop HCC and HB between 17 – 25 months post tamoxifen injections
compared to control Tdg fl/fl mice (Gehan-Breslow-Wilcoxon test: p < 0.0001).
(B) HCC in mice is more prevalent in males compared to female mice.
(C) Hematoxylin and eosin (H&E) stained sections and glutamine synthetase stained sections
indicate that mouse livers contain multiple foci of hepatocellular carcinoma (HCC-1 and HCC-2)
with adjacent normal liver (N).
(D-F) High power image areas of tumors showing H&E stain of normal liver (D), HCC-1 (E) and
HCC-2 (F).
(G-I) High power image areas of tumors of glutamine synthetase staining showing positive zone
three hepatocyte staining of normal liver (G) and complete block staining in hepatocellular
carcinoma HCC-1 (H) and HCC-2 (I).
(J-L) High power image areas of tumors showing reticulin stain of normal liver (J) and HCC-1 (K)
and HCC-2 (L) tumor foci.
(M) Low power hematoxylin and eosin stained section showing mouse liver displaying
hepatoblastoma (HB) with an adjacent foci of hepatocellular carcinoma (HCC) and normal liver
(N).
(N-P): High power image of areas of (N) normal liver, (O) hepatocellular carcinoma and (P)
hepatoblastoma.
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(Q-S): High power image of glutamine synthase staining showing positive zone three hepatocyte
staining in (Q) normal liver, complete block staining in (R) hepatocellular carcinoma and absent
staining in hepatoblastoma (S).
(T-V) High power image areas of tumors showing reticulin stain of normal liver (T) and HCC (U)
and HB (V).
Scale bars: Low power H&E staining images, 1mm; High-power field images, 100 µm.
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3.2.4 Tdg deletion is maintained in aged Tdg fl/-; UB-cre/ERT2+ mice
To determine if TDG protein is reconstituted over the course of aging, it became important
to determine if the Tdg fl/- cells that escape lox-recombination were able to reconstitute TDG over
time. Hence, we prepared lysates from the liver, spleen, brain and lung tissues from control and
TDGKO groups of mice and determined TDG protein levels by western blot (Figure 3.4 A -C). The
above mentioned tissues were analyzed since they exhibit a relatively high level of TDG protein
in control animals (Figure 3.1 E). The average deletion of Tdg remained relatively high in the
tissues tested from 1 - 4 month (early) and 2 year old (end point) mice (Figure 3.1 E, 3.4 A, and
3.4 B). Thus, the Tdg ∆/- cells do not confer an observable competitive disadvantage in comparison
to the Tdg

fl/fl

cells in TAM-treated Tdg

fl/-

; UB-cre/ERT2+ mice. In contrast, the levels of TDG

seemed to rise over time in the spleen which has a relatively high rate of cellular proliferation
(Figure 3.4 B, C). Importantly, TDG levels did not decrease appreciably in tissues with a low rate
of proliferation such as the brain, liver, and lung, which suggests that TDG is less important for
the continued viability of nondividing cells. Together, these results indicate that the loss of TDG
in TDGKO mice is maintained over the aging process, however, rapidly dividing tissues seem to
reconstitute TDG potentially from cells that escaped lox recombination and remained Tdg positive.

3.2.5 Transcriptional profiling of TDGKO mice
The TDGKO mice displayed an increased incidence of HCC compared to the control mice.
The observation that a TDG deletion is maintained over the aging process in mice that eventually
develop HCC prompted us to identify genes that are dysregulated stemming from the loss of TDG.
Hence, we performed RNA sequencing analysis of HCC from TDGKO mice using livers of age/sex
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matched Tdg fl/fl mice as control (Figure 3.5 A - C). The RNA-seq was validated by analyzing the
expression of several upregulated and down-regulated genes with a greater-than-tenfold difference
in expression between the control and TDGKO HCC datasets (Figure 3.5 D, E). The PCA analysis
of the RNA-seq showed that the tumors display a very distinct transcriptional profile compared to
control livers (Figure 3.5 F). Interestingly, among genes with a greater-than-twofold difference in
expression, roughly three-times more genes were found to be downregulated in TDGKO HCC
(Figure 3.5 G). This finding is consistent with the role of TDG as a transcriptional co-activator.
Correlation of the TDGKO HCC transcriptome to previously published datasets (Bhusari et al.,
2013; Thomson et al., 2016) depicted a very disctinct transcriptional profile, although similarities
were found when comparing certain upregulated and downregulated genes (Figure 5 H). These
results suggest that HCC in the TDGKO mice possess a novel transcriptional profile than has been
previously reported. However the majority of these differences could be attributed to aberrant
transcription that is inherent to tumor cells. To establish a causative correlation between TDG
deletion and HCC formation, it became important to identify gene signatures of livers deficient in
TDG. Hence, we extracted livers from TDGKO and control mice four months post TAM injections,
and performed RNA sequencing of the tissues (Figure 3.6 A – B). We identified approximately
1600 differentially expressed genes (q-score < 0.05) (Figure 3.6 C). Hierarchial clustering of the
differentially expressed genes from young (four-months post TAM injections) and endpoint
cohorts of mice showed distinct transcriptional profiles. The RNAseq was found to be highly
reproducible, with replicates from each cohort clustering together and forming distinct groups
depending on the TDG status and age of the mice (Figure 3.6 C). Surprisingly, the differentially
expressed genes resulting from TDG deletion in livers from 4 month old mice appeared to be
further dysregulated upon HCC formation (Figure 3.6 D) . This suggested a potential overlap
117

Figure 3. 4 The conditional deletion of TDG is maintained during aging.

(A) Brain, liver, lung and spleen tissues from control and TDGKO mice were analysed by western
blot with TDG (1:5000) and VINCULIN (1:20000) antibodies. The tissues were harvested at 4
month and 24 months post TAM injections.
(B) Western blot analysis of the brain, liver, lung and spleen tissues from control and TDGKO mice
with HCC (TDG 1:5000 and VINCULIN 1:20000). The control and TDGKO mice are age-matched.
(C) Quantification of western blots (from B) for brain, liver, lung and spleen tissues
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Figure 3. 5 Transcriptome analysis of HCC from TDG knockout mice

(A-B) TDG deletion is maintained in the HCC tumors isolated from TDG knockout mice at the
(A) mRNA and (B) protein level.
(C) RNAseq of HCC from TDG knockout mice and normal age/sex matched control mice.
(D, E) RNA-seq validation using primers against specific upregulated (D) and down-regulated
(E) genes showing a greater than 10-fold change between the control and TDGKO HCC datasets.
(F) PCA plot comparing the expression of control and TDGKO HCC datasets.
(G) A piechart depicting percentage of genes with two-fold difference in expression (Control
FPKM/ HCC FPKM).
(H) Comparison of TDG knockout HCC RNAseq with previously published transcriptome
analysis of HCC in mice. Yellow circle represents microarray of HCC performed by Bhusari et
al. (2015); whereas, the green circle represents genes from the RNAseq performed by Thomson
et al. (2016).
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between gene signatures of TDGKO livers and HCC. Through further statistical analysis, we found
that the transcription profile of a significant number of genes were dysregulated in both TDGKO
livers and HCC (Figure 3.6 E, F). Hierarchial clustering of these genes allowed us to establish a
transcriptional profile that could be differentiated based on TDG status, with the TDGKO livers
clustering much closer with TDGKO HCC than the control groups (Figure 3.7 A). These results
demonstrate that a deletion of TDG causes transcriptional dysregulation in livers that could
potentially predispose them towards HCC.
Pathway analysis of the upregulated and downregulated genes (1.5 fold compared to
control mice livers) was performed using the KEGG and REACTOME databases. Pathway
analysis of downregulated genes showed dysregulation of liver metabolism, retinoid metabolism
and bile acid regulation, as well as, a downregulated p75 NTR receptor signaling (Figure 3.7 B).
Dysregulation of metabolism is a major risk factor of HCC originating via the non-alcoholic fatty
acid liver disease (NAFLD) pathway which occurs predominantly in male patients (Hashimoto et
al., 2009). This finding agrees with our data since a cohort of metabolically relevant genes were
downregulated in TDGKO male mice (Figure 3.7 D), which also displayed an increased onset of
HCC and increased weight compared to age-matched female mice (Figure 3.3 B, 3.7 E, 3.7 F).
Pathway analysis of the upregulated genes upon TDG deletion depicted an increase in several
cancer relevant pathways, such as MAPK and HIPPO signaling (Figure 3.7 C), which are known
to contribute towards increased hepatocyte proliferation and growth (Lu et al., 2010; Zhou et al.,
2009a). These results suggest that the loss of TDG could predispose mice to HCC through noncirrhotic/ fibrotic (NCF)-NAFLD, and could serve as a diagnostic marker of liver cancers
originating via this pathway.
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3.2.6 TDG as a potential prognostic marker of liver cancer in patients
Analysis of the mutational status of TDG in several cancers suggests that a significant
subset of patients with liver cancer have mutations in the TDG gene (Figure 3.8 A). These
mutations could potentially dowregulate the Tdg transcript and affect TDG function. In order to
determine if a lower level of TDG is associated with liver cancer in patients, we analyzed the
TCGA HCC dataset and stratified patients based on their history of liver diseases. In accordance
with our data, TCGA analysis revealed that males without a history of liver disease (no cirrhosis
or fibrosis associated liver damage) have significantly lower levels of the TDG transcript and
higher mortality relative to male/ or female patients with a history of alcoholism or hepatitis
infection (Figure 3.8 B - E). Although it remains unclear if a lower TDG level predisposed these
patients to cancer, this finding agrees with our data that TDGKO HCC shows a male gender bias
and develops from a non-cirrhotic and non-fibrotic pathway.

3.3 Discussion
TDG is a BER protein which has been shown to play an instrumental role in gene
regulation. Studies using mouse models demonstrate that TDG deletion leads to gene specific
DNA hypermethylation and aberrant transcription of developmentally relevant genes, resulting in
embryonic lethality. However, despite its importance the role of TDG in post embryonic
development remains unknown. In this study, we demonstrate for the first time that the conditional
deletion of Tdg in adult mice predisposes them to a high prevalence of HCC through the noncirrhotic/fibrotic (NCF) pathway of liver cancer. High throughput sequencing of tumors
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Figure 3. 6 Transcriptional profile of hepatocytes deficient in TDG compared to TDGKO
HCC

(A) Western blot analysis of the TDG in Tdg fl/fl livers compared to age/sex matched Tdg fl/-; UBcre/ERT2 + (TDGKO) mice livers. Both mice were injected with TAM, as indicated in the
methods section, and allowed to age for 4 months prior to tissue harvest.
(B) The characteristics and identity of mice used for RNA-sequencing analysis. The age of the
mice is indicated post tamoxifen injection. All of the mice were injected at 8 weeks.
(C) Heatmap depicting hierarchial clustering of 1624 differentially expressed genes (identified
from the RNAseq of 4 month old control and TDGKO livers) with endpoint control and TDGKO
HCC transcriptomes. These genes were identified from a cutoff of a q-score < 0.05.
(D) Comparison of the 1624 differentially expressed across all samples. The log10 of fold
changes was used to visualize the downregulated and upregulated genes.
(E, F) Comparison of upregulated and downregulated genes between TDGKO livers and HCC.
The fold-changes of 1625 differentially expressed were generated by dividing the FPKM values
of control samples with age/sex matched FPKM values of TDGKO samples. Genes with a 1.5 and
2-fold difference in expression were then analyzed for overlap between the TDGKO livers and
HCC datasets.
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Figure 3. 7 Gene signature of TDGKO hepatocytes and HCC

(A) Heatmap and hierarchical clustering of overlapping upregulated and downregulated genes
between the TDGKO livers and HCC RNAseq datasets. All of the genes depicted display a 1.5fold difference compared to their respective control cohorts.
(B-C) KEGG and REACTOME pathways analysis of the downregulated (B) and upregulated (C)
genes.
(D) Heat map and hierarchical clustering of several genes relevant to the p75NTR receptor
signaling, metabolism and bile-acid biosynthesis.
(E-F) The conditional deletion of TDG in whole body causes a dysregulation in total body weight
exclusively in the male population (E), relative to the control mice.
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and livers from male mice deficient in TDG demonstrated a defect in metabolism, which is
concomitant with non-alcoholic fatty liver disease (NAFLD) phenotype. Further support for
NAFLD is provided by the finding that the HCC occurred predominantly in male mice, which also
displayed increased weight gain and obesity with age. These findings agree with studies showing
that NAFLD-induced HCC occurs predominantly in males, and is associated with obesity
(Hashimoto et al., 2009; Kettner et al., 2016). In concert with a protective role of TDG against
carcinogenesis in the liver, we find that several of the cancer relevant pathways, such as MAPK
and HIPPO signaling, were upregulated upon TDG deletion in the liver. These findings
demonstrate that TDG plays a tumor suppressive role in the liver tissue, and its deletion leads to a
defect in metabolism relevant genes which potentially predispose these mice to NCF-NAFLD
pathway of HCC.
HCC is the predominant form of liver cancer, and the second leading cause of cancer
related mortalities worldwide (Mittal and El-Serag, 2013), with over 500 million cases per year.
The majority of HCC occurs in a background of hepatic inflammation which is known to contribute
towards tissue damage, scarring (fibrosis) and cirrhosis (Yang et al., 2011). Hepatitis viral
infection and alcoholism are also known to increase the risk of HCC by inducing fibrosis and
cirrhosis. Although HBV infection can cause HCC independent of cirrhosis, the vast majority (70
– 90%) of HBV-induced HCC occurs in cirrhotic livers (Lemon and McGivern, 2012; Mittal and
El-Serag, 2013; Yang et al., 2011). Continued scarring of the liver tissue during cirrhosis leads to
persistent cell regeneration, which contributes towards the malignant transformation of
hepatocytes (Dapito et al., 2012; Haybaeck et al., 2009; Mittal and El-Serag, 2013; Moeini et al.,
2012; Yang et al., 2011).
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In our model, we find that TDG deletion leads to HCC independent of cirrhosis or fibrosis,
which indicates a lack of inflammation induced liver damage. In order to delineate deregulated
pathways upon TDG deletion, high throughput RNA sequencing of the solid tumors and normal
livers was performed followed by gene enrichment analysis. It was found that a loss of TDG leads
to a downregulation of p75NTR signaling. The upregulation of p75NTR signaling pathway has been
directly associated with increased fibrosis and cirrhosis in patients (Amoras et al., 2015), hence, a
downregulation of this pathway agrees with a lack of cirrhosis/fibrosis in TDGKO livers. In
addition, both the MAPK and HIPPO signaling pathways were found to be upregulated which have
been previously implicated in liver cancer by contributing towards increase hepatocyte
proliferation and loss of cell cycle control (Delire and Stärkel, 2015; Zhou et al., 2009b). In Hippo
signaling, the MST1 and MST2 kinases, along with LATS1/2 and MOB1 regulate the activation
of YAP/TAZ oncogenes (Zhou et al., 2009a). Several studies have demonstrated that YAP/TAZ
activation directly promotes liver outgrowth and spontaneous HCC in mice (Lu et al., 2010; Zhou
et al., 2009a). These oncogenes are also known to trans-activate the MAPK signaling to promote
HCC in mice (Moeini et al., 2012; Zhang et al., 2015; Zhou et al., 2009a), indicating a potential
for crosstalk between the two pathways. These findings suggest that TDG potentially function as
a tumor suppressor in liver via suppression of the HIPPO and MAPK signaling pathways.
Downregulation of several metabolism relevant genes was also found upon TDG deletion
in the liver tissue, which is known to cause metabolic syndrome in humans and mice (Phillips et
al., 2006). Metabolic syndrome is generally associated with central obesity, with an accumulation
of the adipose tissue particularly around the waist and trunk. Metabolic syndrome leads to a defect
in glucose metabolism and insulin resistance, and is the number one cause of liver cancers that
originate via the NAFLD pathway (Kettner et al., 2016). NAFLD is found in approximately 30 –
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Figure 3. 8 Relationship between TDG levels and clinically aggressive form of HCC.

(A) Mutation analysis of the TDG gene in tumors reveals that it is commonly mutated in liver
cancer, as well as other tumors
(B-C) Male HCC patients with no history of liver disease die significantly faster compared to
male patients with alcoholism/hepatitis induced HCC (B) and females with no history of liver
disease (C).
(D-E) Male patients with no history of liver disease possess statistically significant lower Tdg
mRNA levels compared to patients with cirrhosis dependant HCC with a history of alcoholism or
hepatitis B/C infection (Males in D, Females in E).

130

131

40 % of the general population and up to 95 % of those with morbid obesity (LaBrecque et al.,
2014). Excessive fat accumulation induces liver injury, inflammation and regeneration, which
leads to cirrhosis and fibrosis in a process called non-alcoholic steotohepatitis (NASH) (Kettner
et al., 2016). Although NAFLD can progress to HCC through NASH, there are a subset of patients
with NAFLD that develop HCC independent of NASH, however, the mechanism remains unclear
(Guzman et al., 2008). Our study provides evidence that a loss of TDG potentially leads to a
metabolic syndrome and NAFLD in mice through downregulation of genes important in
metabolism. This in turn facilitates an onset of HCC through the novel NCF-NAFLD pathway that
is independent of cirrhosis/NASH.
The lack of proper mouse models that develop NAFLD from metabolic syndrome has
significantly delayed our understanding of metabolism induced hepatocarcinogenesis. In this
study, we demonstrate for the first time that TDG deletion leads to liver cancer in mice that involve
a dysregulated NCF pathway that includes several metabolism related genes characteristic of
NAFLD associated HCC. Consistent with these findings, TCGA analysis revealed a reduction of
Tdg transcript in male patients that develop HCC from the NCF pathway, although evidence of
NAFLD was inconclusive in these patients. These patients were found to have a clinically worse
outcome compared to females without a history of liver disease, or patients with cirrhosis induced
HCC (Alcoholism or HBV/HCV infection). DNA methylation patterns are known to be
deregulated in a host of tumor types, including HCC (Lian et al., 2012; Sproul and Meehan, 2013;
Thomson et al., 2016). In addition to changes in DNA methylation, recent studies show that levels
of 5hmC are reduced in rapidly proliferating hepatocytes that have undergone hepatectomy (Neri
et al., 2015; Nestor et al., 2015; Thomson et al., 2016). This is significant since a reduction in
5hmC levels has previously been linked to an elevated rate of proliferation in tumor cells (Lian et
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al., 2012). These findings suggest that deregulation of active DNA demethylation pathway could
be a potential precursor to HCC formation. Future studies are necessary to determine if TETs and
TDG play a role in maintaining epigenetic stability in hepatocytes, and if deregulation of the
methylome is sufficient in predisposing mice to HCC in vivo.

3.4 Methods
3.4.1 Generation of the TDGKO mice
All mouse experiments were done in compliance with the Institutional Animal Care and
Use Committee guidelines at London Regional Cancer Center at Western University. For the
conditional deletion of Tdg, Tdg fl/fl mice were bred with UBC-cre/ERT2 mice to generate Tdg fl/fl;
UBC-cre/ERT2+ mice. These mice were then bred with the Tdg+/- mice to generate the Tdg

fl/-

UBC-Cre/ERT2+ experimental genotype. The Tdg+/- mice were generated by mating the Tdg

+/fl

;

mice with a deletion cre mice. In this model, exon 2 of Tdg is targeted for deletion, which has
previously been shown to generate an efficient knockdown of the TDG protein. The UBCcre/ERT2 mouse line utilizes the ubiquitin C promoter to express a tamoxifen inducible form of
cre (cre-ERT2) in the whole body, which translocate to the nucleus upon activation and catalyzes
the recombination of loxp sites to facilitate protein deletion (Ruzankina et al., 2007). In this
experiment, adult (8 weeks old) Tdgfl/-;UB-Cre/ERT2+ and age/sex matched Tdg fl/fl controls were
intraperitoneally injected with 3 mg TAM daily for 5 days to facilitate efficient TDG deletion, and
then monitored during the course of aging.
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3.4.2 Immunohistochemistry (IHC) and Reticulin Staining
Immunohistochemistry was performed on unstained formalin fixed, paraffin embedded
sections of tissues. Briefly, 4 µm sections of the tissues were collected on charged glass slides and
then were de-paraffinzed in xylene and rehydrated through a decreasing graded ethanol series. This
was followed by heat-induced antigen retrieval. Then the tissue section was incubated with 3%
peroxide blocking solution to block endogenous peroxidase activity. Immuno-blotting was then
performed using glutamine synthetase and anti-rabbit secondary antibody (1:1000). The tissue
sections were then incubated with peroxidase substrate (ImmPACT DAB Vector Laboratories SK4105) and 3,3-diaminobenzidine (DAB) was used to visualize all immune reactions. The tissue
sections were counterstained with hematoxylin.
The reticulum stain was performed using the reticulum stain kit as per manufacturer
guidelines (Abcam, AB150684). Briefly the tissue sections were deparaffinized and then
rehydrated in increasing ethanol series. The tissue slides were incubated in potassium
permanganate solution, followed by potassium metabisulfite solution until the section went
transparent. The tissue was then incubated with ferric ammonium sulfate, ammoniacal silver,
formalin, gold chloride and sodium thiosulfate solution with intermittent rinsing with distilled
water. The slides were counterstained using nuclear fast red solution and then dehydrated with
absolute ethanol. The sections were then mounted in synthetic resin for imaging.

3.4.3 qPCR
Total RNA from tissues was extracted using an RNAzol solution as per manufacturers
protocol (ThermoFisher). Prior to RNA extraction, the tissues were flash frozen in RNAzol and
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kept at -80 oC. The cDNA was synthesized using the Applied Biosystems Reverse Transcription
Kit as per manufacturer guideline. Quantitative PCR wase performed using a SYBR Greendetection system (Applied Biosystems) using primers outlined in Table 3.2. Transcript abundance
was normalized to Gapdh mRNA.

3.4.4 RNA sequencing and Bioinformatic analysis
For the RNA-seq, the sample quality was assessed using the Agilent 2100 Bioanalyzer.
Qualifying samples were then prepped following the standard protocol for the NEBnext Ultra ii
Stranded mRNA (New England Biolabs). Sequencing was performed on the Illumina NextSeq 500
with Paired End 42bp × 42bp reads. The raw data was aligned to the mm10 mouse genome using
the STAR aligner and gene list was generated using cufflinks. Differentially expressed gene list
was generated using q < 0.05 as the cutoff for significance. The heatmap was generated using the
Bioconductor gg-plot addon for the R software and Morpheus from broad institute. For the TCGA
analysis, the data was downloaded using the firehose website, and analyzed using the R-software.
GraphPad PRISM 5.0 was used for generating the Kaplan-Meier curves.

3.4.5 Immunophenotyping
The mice were euthanized and within 15 minutes, the spleen tissue was harvested and
placed in 3 ml ice-cold 1 X PBS buffer. Samples were then homogenized and transferred to 14 ml
BD falcon tubes. Then, 2 ml of the ACK lysis buffer (150 mM NH4Cl, 0.01 mM NaHCO3, 0.2
mM EDTA) was added and cells were incubated on ice for 5 min to facilitate red blood cell lysis.
Samples were then spun down at 2100 rpm and re-suspended in 1 ml FACS buffer (10 % FBS, 2
mM EDTA in 1x PBS buffer) and cells counted. After counting the number of cells, the samples
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were spun and re-suspended at 10,000 cells / µl and 50 µl was added per well (1 million cells) in
a 96 well plate. The cells were treated with 1 µg of FC block (CD16/32) for 15 min, then incubated
with the antibody cocktail (CD45-PE Cy7, CD3-FITC, CD19-APC, CD14-PE—1 µg each in
FACS buffer) for 1 hr on ice in dark and then washed twice with FACS buffer. Samples were then
analyzed on BD-FACS 4 color flow-cytometer in triplicates. Unstained samples (i.e. samples
treated with FC block but not the antibody cocktail) are used as negative control

3.4.6 Statistical analysis
The data represented in qPCR (for mRNA expression) and Image J western blot
quantification figures, using the vinculin for normalization, are representative of at least three
independent biological replicates. For the 3C experiment, the data from gel electrophoresis was
assessed by the ImageJ software, using the untreated lane for normalization. All western blots are
representative of at least duplicate experiments. Statistical analyses were performed using
GraphPad Prism 5.0, employing the Student’s t-test (2 groups), or ANOVA with Tukey post-hoc
(3 groups or more). All p-values over 0.05 were deemed not significant. Significance is indicated
as follows: *, p < 0.05; NS: not significant.
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Table 3. 1 List of qPCR primers used in this chapter

Forward (5’ – 3’)

Reverse (5’ – 3’)

Gapdh

AAGGTCATCCCAGAGCTGAA

CTGCTTCACCACCTTCTTGA

Lef1

TCTGCCCTGTGAAGTGTCTG

AATGAACTGCAAACGGGTTC

Tet1

ACCACCCAGATCATCCCATA

CCTGTCTCAGTCCCTCAAGC

Tenm4

CAGCCTGTGACTTCCTCCTC

CTTGCCTGTTTCCTCTCTGG

Dkk3

TGAGGCAGTGGCTACACAAG

GCTGGTATGGGGTTGAGAGA

Rac3

ACTGCTGGCCAGGAAGACTA

CAGAAGGATGGGTGTGTGTG

Hey 2

ACCAGAGGCTCATTGACACC

CCTCTCCCCAAAACAGACAA

Bmp7

CAGACCAACCTCTCCTGAGC

AGGCTTGCGATTACTCCTCA

Mst1

CTGATTTGCCTGCCTCCTGAAC

AGGACTGTGTTATTGCTTGTACC

Primer
Name

G
Cyp2c2

TCAGCCAATCCTTCACCAACTTC

ACCCGTGCAATATGACAGTAGGC

TGGCAGGTCAACCATGATGAGAA

CTTTCCCAAGCCGAAGAGCATC

9
Cyp1a2

G
Aaas

TGGAGACTTCAACGGCTTCTCG

GCCTTTGGCTTCAATTTCACCATC

Cyp2c7

TCCTTCACCTCGTAAGACAACGC

TGCCATTACACTTGTGCCCTTGG

0
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Table 3. 2 List of antibodies used for immunophenotyping experiments

Antibody

Company

Catalogue number

CD3 – FITC

BD Pharmingen

561798

CD45-PE-Cy7

BD Pharmingen

552848

CD8a-PE-Cy7

BD Pharmingen

552877

CD4-PE

BD Pharmingen

553048

CD16/CD32 (Fc

BD Pharmingen

553141

BD Pharmingen

561736

Block)
CD19-PE

Table 3. 3 List of antibodies used in this chapter

Antibody

Species

Company

Catalogue No.

TDG mouse

Rabbit

Homemade

N/A

Vinculin

Mouse

Sigma

V9264

Glutamine

Mouse

Santa Cruz

Sc-74430

Mouse

Vector Labs

MP-2400

Synthetase (GS)
Mouse on Mouse
ImmPRESS
HRP
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Chapter 4: General Discussion
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The epigenetic control of gene transcription involves changes in DNA methylation and/ or
histone tails modification and is important for a variety of biological process. Although histone
modifications were known to be dynamic, the 5mC mark was always considered a relatively stable
DNA mark. Recent studies has shed light on the plasticity of DNA methylation during
development, differentiation, somatic cell reprogramming and tumorigenesis (Cortázar et al.,
2011; Cortellino et al., 2011; Gu et al., 2011; Hassan et al., 2017; Hu et al., 2014; Métivier et al.,
2008). The active DNA demethylation system facilitates the modification or removal of the 5mC
mark and was found to be critical for these biological processes. For instance, studies show that
cellular reprograming and signaling in response to stimuli, such as retinoic acid and estrogen, is
dysregulated upon TDG and/ or TET1/2/3 deletion (Hassan et al., 2017; Hu et al., 2014). TET3
was found to be critical for methylation erasure of paternal genomes in the primordial germ cells,
and TET3 KO mice display developmental abnormalities (Gu et al., 2011; Tsukada et al., 2015).
Beyond embryonic development, studies have shown that a loss of TETs affect MET (Hu et al.,
2014), as well as, the reprogramming of MEFs and that TET1/2 act as tumor suppressors of the
hematopoietic system in mice (Cimmino et al., 2015; Lian et al., 2012; Rasmussen et al., 2015;
Weissmann et al., 2012). Studies on AML have shown that disease progression involves a drastic
loss of 5hmC (Lian et al., 2012), which correlates with a decline in TET2 transcription (Weissmann
et al., 2012). These studies promote TET proteins as important epigenetic regulators in cells and
potential biomarkers and predictors of hematopoietic cancers.
Research examining active DNA demethylation has increased tremendously since its
discovery, yet much of the focus has been on TET proteins and very few studies report on the
physiological relevance of TDG. This is surprising since TDG was found to be essential for
embryonic development and maintenance of epigenetic stability in cells, which underscores its
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importance in active DNA demethylation and development (Cortázar et al., 2011; Cortellino et al.,
2011). In addition to its glycosylase activity, TDG has an elaborate interaction networks which
involves nuclear receptors, co-activators, and proteins within the DNA demethylation, BER, and
NER machinery. Studies have shown that TDG functions as a scaffolding protein at certain genes
by facilitating complex stability of co-activators such as CBP, MLL1 and TET2 (Cortázar et al.,
2011; Hassan et al., 2017). Thus, TDG participates in events that extend beyond active DNA
demethylation, which begs into question whether its dual catalytic and scaffolding activities are
important in gene transcription. In this study, I identified the Hic1 gene as a direct RAR-dependent
target for TDG and show that the dual catalytic and scaffolding activities of TDG are required for
RA-dependent gene expression of HIC1 (Chapter 2). In addition, using a conditional knockout
mouse model of TDG, I study the role of TDG beyond embryonic development and demonstrate
that its deletion predisposes mice to a high prevalence of HCC (Chapter 3).

4.1 The catalytic and scaffolding activities of TDG are important for gene transcription
Retinoic acid (RA) plays critical regulatory role in a variety of biological process, such as
establishment of the body plan during embryonic development and cell cycle control (Tang and
Gudas, 2011;Li et al., 2004; Suzui et al., 2004). The bioactivity of RA is mediated primarily by
heterodimers of RAR/RXR heterodimers, which regulate the transcription of its target genes by
recruiting coregulatory proteins, such as CBP and TDG. Previous studies show that TDG is
important in retinoid signaling events by facilitating the recruitment of certain co-activators and
maintaining protein complex stability at target genes. Retinoid signaling was found to be
compromised upon TDG deletion in MEFs, with several of the genes in the retinoid pathway being
silenced upon TDG deletion (Cortazar et al., 2011). These studies suggest that TDG potentially
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functions as a scaffold and glycosylase in RA signaling cascades. In my study, I identified
hypermethylated in cancer 1 (Hic1) as novel RA inducible target and show that active DNA
demethylation occurs during Hic1 transcription. I found the excision of active demethylation
metabolites 5fC/5caC at the Hic1 promoter and the recruitment of certain RAR co-activators are
TDG dependent (Hassan et al., 2017). Overall, this study provides evidence that the dual catalytic
and scaffolding activities of TDG are essential in retinoid signaling events.
HIC1 is a candidate tumor suppressor (Britschgi et al., 2008), and its expression is often
lost in solid human cancers as a result of DNA hypermethylation of its P0 promoter (Aggerholm
et al., 2006; Chen et al., 2003; Cheng et al., 2014; Jenal et al., 2010). In my study, I found that
treatment of MEFs with RA led to the recruitment of an RAR complex consisting of TDG, the
lysine acetyl transferase CBP, RXR, and TET1/2 to a conserved RARE upstream of the Hic1 P0
promoter (Figure 4.1). The RAR complex displaced DNMT3a and led to a loss of 5mC with a
concomitant upregulation of 5fC/5caC at the P0 promoter. Through time-course methylase assisted
bisulfite sequencing (MAB-seq), I showed that although the 5fC/5caC metabolites continue to
accumulate in the absence of TDG, their subsequent removal is blocked. Using kinetic ChIP
experiments, I found that the generation of these metabolites correlated with TET2 localization,
which shows that TET2 participates in 5mC oxidation at the Hic1 promoter. These findings
demonstrate that the glycosylase activity of TDG is required for Hic1 transcription in response to
RA. In addition, RAR complex stability was hindered in the absence of TDG, since the recruitemnt
of CBP and TET2 was abrupted in TDG knockout MEFs. Overall, these findings demonstrate that
the dual catalytic and scaffolding properties of TDG are important for gene regulation in response
to RA, and that TDG plays a critical role in active DNA demethylation via regulating 5fC/5caC
turnover in MEFs (Hassan et al., 2017).
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Future studies utilizing targeted mutations are necessary to determine if both the catalytic
and scaffolding activities of TDG are important for gene transcription. Cortellino et al. (2012)
showed that the catalytic activity of TDG is dispensible for embryonic development, however,
very little is known about its scaffolding function. It would be interesting to determine if perturbing
the interaction network of TDG can cause embryonic lethality, or lead to specific disease states.

4.2 Is TDG a tumor suppressor or an oncogene?
TDG was initially identified as a base excision repair (BER) protein, involved in the removal
of mutagenic G:T and G:U mispairs from DNA. However, TDG knockout studies demonstrated
that its deletion does not contribute to increased mutational load in cells, which is inconsistent with
its classical base repair function (Cortázar et al., 2011). In concert with these findings, irradiation
of Tdg null MEFs did not lead to genomic instability or a loss of proliferation compared to wildtype MEFs (Cortázar et al., 2011). This was surprising since MBD4 deletion, which is a functional
homologue of TDG, leads to random CpG mutations from a dysfunctional BER pathway and an
onset of colorectal cancer in mice (Wong et al., 2002). Through these observations it became
apparent that although TDG participates in base repair, its loss doesn’t contribute to a
dysfunctional BER pathway potentially through redundancy within the system.
In addition to its role in BER, TDG appears to be involved in pathways that are relevant in
both tumor progression and suppression. For instance, TDG was found to potentiate p53 dependent
activation of p21 (da Costa et al., 2012) and promote the transcription of RARβ, p15ink4b, p16ink4a,
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Figure 4. 1 The regulation of HIC1 transcription in response to RA is TDG dependant.

The treatment of MEFs with RA leads to the recruitment of an RAR complex consisting of TDG,
TET1/2, CBP and RXR. This binding correlates with chromatin looping which connects the distal
RARE with RARE at the Hic1 locus, and active demethylation of its P0 promoter. The recruitment
of CBP and TET2 appears to be TDG dependent. In addition, the TET2 localization was found to
be transient and concomitant with generation of the 5fC / 5caC metabolites a the P0 promoter.
This model provides evidence of the dual catalytic and scaffolding activities of TDG in gene
transcription, and demonstrates a novel dynamics of active DNA demethylation in response to
cellular stimuli.

150

151

and Hic1 tumor suppressor genes (Cortázar et al., 2011; Hassan et al., 2017; Thillainadesan et al.,
2012; and unpublished data). These findings would be consistent with a tumor suppressor function
of TDG. In contrast, evidence indicates that TDG potentiates Wnt signaling cascades through its
interaction with TCF4 (Xu et al., 2014), which is concomitant with increased TDG expression in
high grade colorectal cancers. In addition, TDG has been shown to play a role in estrogen signaling
cascades (Métivier et al., 2008), which are important for breast cancer proliferation and invasion.
evaluate its role in development, it became necessary to generate a mouse model of Tdg deletion.
In order to analyze the role of TDG in vivo, we generated a conditional knockout mouse
model (Tdg

fl/-

; UB-cre/ERT2+) to circumvent embryonic lethality. We injected these mice with

tamoxifen once they reached maturity (8 weeks) and then monitored their development over a
period of 2 ½ years. After roughly 20 months post tamoxifen injections, the mice began to exhibit
an increased prevelance of hepatocellular carcinoma (HCC) and hepatoblastoma (HB).
Surprisingly, males had nearly four times higher incidence of HCC relative to female mice.
Pathology of tumors stained positive for complete glutamine synthetase staining, and either absent
or greater than 3 cell-thick trabeculea (reticulin stain), which is consitent with an invasive and
metatastatic liver cancer. HCC was also found to occur independant of cirrhosis or fibrosis induced
liver scarring.

RNA sequencing followed by pathway analysis revealed dysregulation in

metabolism and upregulation of MAPK and HIPPO signaling pathways, which have been directly
implicated in liver cancer. The defect in metabolism relevant genes provides evidence of NAFLD
in TDGKO mice, which is known to occur predominantly in males. However, future studies are
necessary to validate the onset of NAFLD in TDGKO mice through histological (Oil red O-stain)
and serum analysis (carnitines, lipids, prostaglandins, CoAs and TCA metabolites) to establish a
defect in liver metabolism. These studies could generate novel mechanistic insights into NAFLD
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associated HCC that occurs indepandant of cirrhosis induced NASH, and provide potential
biomarkers and/or druggable targets in liver cancer.

4.3 TDG as a tumor suppressor in vivo
In the first part of my studies, I showed that TDG is important for recruiting the coactivators CBP and TET2, as well as, regulating the levels of 5fC / 5caC at the Hic1 locus in
reponse to RA. HIC1 functions as a tumor suppresor in vivo, and is known to be frequencly
silenced in cancers as a result of promoter DNA hypermethylation (Chen et al., 2003) Surprisingly,
the Hic1 promoter was found to be hypermethylated in TDG knockout HCC relative to agematched normal liver (Figure 4.2). This finding is in agreement with my study on the role of TDG
in retinoid signaling events in MEFS showing that a deleiton of TDG in vivo leads to Hic1 silencing
via promtoer DNA hypermethylation (Chapter 2, Figure 2.14). This indicates that TDG deletion
promotes the targeted silencing of tumor suppressor genes by DNA hypermethylation in vivo,
which could be a contributing factor to HCC arising from a deficiency in TDG. In addition, these
findings demonstrate that a loss of TDG in adult mice potentially deregulates retinoid signaling
events, which is a known feature of liver cancers (Shirakami et al., 2015).
The onset of liver cancer in TDG deleted mice is in stark contrast with deletion of other
members of the active demethylation machinery that are associated with an immune-related
phenotype. The reason for these differences are currently unclear. It is conceivable that unlike the
immune system where a loss of TDG could be compensated by redundant pathways or proteins,
such as MBD4, it plays a very particular role in hepatocytes. Through RNAseq on livers, I found
that a series of genes encoding liver metabolism enzymes were downregulated upon TDG deletion
(Chapter 3, Figure 3.7D). In addition, genes important for retinol metabolism, such as Rbp1, Bco2
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and Lrat, were all downregulated in TDG null livers (Chapter 3, Figure 3.7 D) consistent with
previous observations. It has been established that retinoids regulate the expression of a multitude
of genes associated with fat metabolism, and many studies support the relationship between
defective retinoid signaling and liver disease (Shirakami et al., 2015). For instance, studies suggest
that BCO, which is an enzyme responsible for cleaving provitamin A carotenoids to retinoids, has
a role in modulating hepatic fat metabolism (Hessel et al., 2007). BCO mutant mice were found
to possess a fatty liver and are more susceptible than control mice to high fat diet-induced
impairments in fatty acid metabolism (Hessel et al., 2007). Consistent with this finding, an analysis
of hepatic transcriptional profile of NAFLD patients indicated that retinoids have important roles
in mediating normal lipid metabolism in the liver and that altered retinoid signaling is associated
with a progression of NAFLD (Ashla et al., 2010). In addition, a study on insulin resistance
demonstrated that an oral administration of ATRA significantly improved insulin sensitivity in a
diet-induced mouse model of NAFLD (Tsuchiya et al., 2012), which indicates that retinoids may
stimulate insulin sensitivity to counteract the onset of NAFLD in mice. Since TDG plays an
essential role in retinoid signaling, it is conceivable that a loss of TDG predisposes mice to NAFLD
due to dysregulated retinoid metabolism. Additional studies, involving ChIP and genome-wide
bisulfite sequencing, are needed to address the role of TDG in the control of metabolism relevant
genes, and if TDG levels correlate with lost sensitivity to retinoid signaling events, metabolic
syndrome and NAFLD associated HCC in mice.
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Figure 4. 2 Transcriptional silencing of HIC1 in TDG knockout HCC

(A) Bisulfite sequencing of Hic1 P0 promoter of HCC shows greater than 90 % methylation
compared to age, and sex matched normal control liver
(B) HIC1 is silenced in tumors with a hypermethylated P0 promoter relative to normal livers of
age and sex matched control mice
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APPENDIX 1: Hepatocellular Carcinoma in Tdg fl/-; UB-cre/ERT2+ mice
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Figure 5. 1 Identity of the Tdg fl/-; UB-cre/ERT2+ (TDGKO) mice with hepatocellular
carcinoma and/or hepatoblastoma
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